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ABSTRACT 
Stephanie Ann Kramer: Synthesis of Polymeric Materials for Drug Delivery and 
Industrial Applications 
(Under the direction of Wenbin Lin and Michel R. Gagne)  
 
 
This dissertation reports the synthesis of polymeric materials for industrial and 
medicinal applications. Depending on their chemical structure, polymers have different 
properties and applications. Polyolefins, used in packaging and films, are one of the most 
highly produced polymeric materials in industry, whereas only a handful of polymeric 
materials are in the market for drug delivery.  
The first part of this thesis presents a method to deoxygenate linear polyols producing 
branched polyolefins. In Chapter 2, linear polyols, such as poly(vinyl alcohol) (PVA), are 
hydrosilylatively deoxygenated using catalytic amounts of B(C6F5)3 and a reducing 
hydrosilane. Following reduction, a highly branched, predominantly saturated structure is 
obtained. Depending on the alcohol-protecting group and the hydrosilane used, the branch 
numbers can exceed 200 branches per 1000 carbons. The branching microstructure is also 
dependent on the protecting group and silane. For instance, the deoxygenation of TMS-
protected PVA with diethylsilane produced a polymer with different branch types when 
compared to the polymer that results from the deoxygenation of TES-protected PVA.  
The B(C6F5)3-catalyzed deoxygenation was applied to a triblock system wherein the 
central block was a 1,5-polyol structure to produce otherwise inaccessible triblock polymers 
with an amorphously branched interior block (Chapter 3). The starting polymer was obtained
 iv 
 by sequential hydroboration/oxidation of poly(styrene-b-butadiene-b-styrene) (SBS), which 
converts the polybutadiene block into a 1,5-polyol block. The hydroxylated SBS polymer 
was then completely deoxygenated to yield a novel triblock polymer with a highly branched 
interior, with the branching being predominantly butyl or longer chains as established by 13C-
NMR spectroscopy. The structure-property relationships of this new triblock system still 
need to be investigated and compared to SBS. The second section of this thesis discusses an 
alternative drug delivery approach utilizing nanoscale coordination polymers (NCPs). 
Chapter 4 presents the synthesis of Ca(II) and Mn(II)-based NCP formulations containing a 
cisplatin prodrug. Coating the NCPs with a lipid bilayer stabilized both of these formulations. 
Drug release profiles demonstrated sustained cisplatin release from the NCPs.  Drug loadings 
of 20% for Ca-based NCP and 25% for Mn-NCP were determined. Due to the exceptionally 
high drug loadings and nanoscale size, these cisplatin NCPs are promising drug delivery 
candidates.  
 v 
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 SYNTHESIS OF POLYMERIC MATERIALS FOR DRUG DELIVERY AND Chapter 1.
INDUSTRIAL APPLICATIONS 
1.1  Introduction 
The properties of polymers are highly varied, as are their applications, which range 
from synthetic plastics to rubbers to natural biopolymers (e.g. DNA) to lubricants. The 
properties and hence the application of polymers depends exquisitely on the polymer 
composition and microstructure. With few exceptions, one normally associates the monomer 
units with the composition of a polymer, though as described herein, this is not always the 
case. The microstructure on the other hand typically reflects how the monomers are arranged 
within the chain (e.g. tacticity), but this can also be ambiguous. This dissertation will discuss 
two different applications of polymeric materials (industrial polyolefins and drug delivery 
nanoscale coordination polymers), and in particular, the former materials in this chapter will 
be shown to significantly digress from their nominal “repeat unit” formulations. 
1.2  Polymer Defunctionalization 
1.2.1 Polyolefins 
Polyolefins are used in a variety of applications, including industrial lubricants, 
grocery bags, engineering plastics, and adhesives. Despite their wide range of uses, 
polyolefins are composed only of carbon and hydrogen atoms, yet it is the connectivity and 
structure of the polymer that determines its properties, and consequently its use. Simply 
manipulating how the monomer units are bound in the chain can produce material with 
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wildly varying properties. For instance, low-density polyethylene (LDPE) contains short 
chain branches, giving it properties that make it useful in plastic wraps. On the other hand, 
the minimal short chain branches in high-density polyethylene (HDPE) produces a more 
dense material that finds use in plastic storage containers (e.g. milk jugs).  
The synthesis of branched polyolefins typically involves polymerization of olefinic 
monomers using metal catalysts.1 Coordination catalysts, which enchain alkene monomers 
via coordination-insertion mechanisms allow for greater control over the polymer structure 
when compared to free radical initiators. Depending on the catalyst selected, control over the 
connectivity of the monomers, and therefore the polymer properties, can be achieved.  Initial 
olefin polymerization catalysts were discovered in the 1950s by Ziegler2 and Natta3,4 
(Ziegler-Natta catalysts) and by Hogan and Banks (Phillips catalysts)5. The extensive 
development and optimization of these and many other families of polymerization catalysts 
have fed the enormously important polyolefin business that exists today. Polymerization with 
coordination catalysts involves coordination of the monomer to the active metal site, 
followed by insertion into the metal-carbon bond at the active end of the polymer chain. The 
stereo- and regiochemistry of monomer coordination is what controls the propagation and 
structure of the resulting polymer chain. 
                                                
1 Vasile, C., Ed. Handbook of Polyolefins; Marcel Dekker, Inc: New York, 2000. 
 
2 Ziegler, K.; Holzkamp, E.; Breil, H.; Martin, H. Angew. Chem. 1955, 67, 541-547. 
 
3 Natta, G. J. Polym. Sci. 1955, 16, 143.  
 
4 Natta, G.; Pino, P.; Corradini, P.; Danusso, F.; Mantica, E.; Moraglio, G. J. Am. Chem. Soc. 
1955, 77, 1708. 
 
5 Hogan, J.; Banks, R. US Patent 2,825,721, March 4, 1958. 
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Polymerization of ethylene, using different coordination catalysts, provides a 
synthetic route to produce polymers with unique microstructures and compatibility with polar 
solvents depending on the catalyst selected. Traditional approaches, such as Ziegler-Natta 
catalysis, of olefin polymerization allow for production of linear unbranched polymers at 
atmospheric pressures. In 1953, Ziegler discovered that a titanium catalyst together with an 
aluminum alkyl co-catalyst result in the polymerization of high molecular weight HDPE.2 
Later, Natta extended that this catalytic system to other olefins, such as polypropylene.3,4,6 
Second-generation catalysts were developed to increase the catalyst activity to efficiencies to 
100-1000 kg polymer per gram of titanium, eliminating the need to remove residual catalysts 
from the final polymer.7 Figure 1.1 presents a proposed general mechanism for the Ziegler-
Natta catalysis of polyethylene.8 The first step of the polymerization reaction is catalyst 
initiation, in which the alkyl aluminum co-catalyst serves to activate the titanium catalyst by 
acting as a Lewis acid to abstract a chloride, producing a vacant site for ethylene 
coordination. Although the exact mechanism is unknown, polymer chain growth is believed 
to occur at vacant Cl sites at the titanium surface through migratory insertion reactions. For 
migratory insertion reactions to occur, the polymerization catalyst must have an extra empty 
orbital after coordination of ethylene. The alkyl group forms an agostic C-H bond interaction 
with the empty orbital on the titanium metal tilting the sp3 orbital away from the metal to 
promote migratory insertion. The polymer chain is terminated through either β-hydrogen 
                                                
6 Natta, G. J. Polym. Sci. 1959, 34, 21-48. 
 
7 Albizzati, E.; Galimberti, M. Catal. Today 1998, 41, 415-421. 
 
8 Shamiri, A.; Chakrabarti, M.; Jahan, S.; Hussain, M.; Kaminsky, W.; Aravind, P.; Yehye, 
W. Materials 2014, 7, 5069-5108. 
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elimination to produce polyethylene with a terminal C=C bond or, more commonly, through 
the use of hydrogen as a chain transfer reagent.9 
 
Figure 1.1. Proposed mechanism of Ziegler-Natta polymerization of ethylene. 
 
The controlled synthesis of branched polyethylene was first reported by Brookhart. Ni 
and Pd α-diimine catalysts were developed to polymerize olefins in a living fashion to yield 
high molecular polymers with a narrow weight distribution.10 Incorporation of the bulky 
diimine ligands into the catalyst allowed for synthesis of highly branched polymers through a 
chain walking mechanism (Figure 1.2).10,11,12,13 It is well established that the metal is able to 
                                                
9 Santos, L. J. Braz. Chem. Soc. 2011, 22, 1827-1840. 
 
10 Johnson, L.; Killian, C.; Brookhart, M. J. Am. Chem. Soc. 1995, 117, 6414. 
 
11 Guan, Z.; Cotts, P.; McCord, E.; McLain, S. Science 1999, 283, 2059. 
 
12 Ittel, S.; Johnson, L.; Brookhart, M. Chem. Rev. 2000, 100, 1169-1203. 
AlR3
-AlR2Cl
LnTi Cl LnTi R
Initiation:
Propagation:
Ti CH3 Ti CH3
insertion Ti
Ti
insertionTi
2chain growth
Termination:
n
Ti H + n
H2 Ti H + n
Ti
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migrate or “walk” along the polymer chain through insertion and β-hydride elimination 
reactions. The two late transition metal catalysts demonstrate different polymerization 
behaviors. In the case of the Ni(II) system, the degree of branching and branching 
microstructure was manipulated by controlling the ethylene pressure and temperature during 
the polymerization reaction. Increasing the ethylene pressure during the reaction lead to a 
polymer with a decrease in branch number and a linear topology with mostly short branches. 
At reduced ethylene pressures, dense, hyperbranched polymers were produced. Depending 
on the reaction conditions selected, the synthesized polyethylene ranged from linear to a 
highly branched (>120 branches/1000 C) structure. When the Pd(II)-catalyst was used in 
ethylene polymerization, the degree of branching (100 branches/1000 C) was essentially the 
same for all reaction conditions. 
 
Figure 1.2. Mechanism of α-diimine Ni/Pd-catalyzed olefin polymerizations. 
 
Due to their importance in defining properties, methods for characterizing the defects 
or branches in a polyolefin, such as polyethylene, have been developed with 1H- and 13C-
NMR spectroscopy being particularly useful.  A branch is defined as the number of carbons 
from a methyl to a methine off of the backbone, and the number of these per 1000 C is a 
                                                
13 Gates, D.; Svejda, S.; Onate, E.; Killian, C.; Johnson, L.; White, P.; Brookhart, M. 
Macromolecues 2000, 33, 2320. 
M
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N R insertion
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benchmark measure. This is typically quantitated in the 1H-NMR spectrum by integration of 
each proton type.14 For example, the degree of branching can be estimated from the ratio of 
methyl hydrogens (~0.85 ppm) to the total aliphatic hydrogens in the polymer by a specific 
formula. The equation used to calculate the degree of branching in this work is shown in 
Equation 1.1. A higher ratio of methyl to total hydrogens indicates a greater degree of 
branching.  
Equation 1.1. 
 
Adding chromium(III) acetylacetonate to an NMR sample containing a polyethylene 
sample prior to obtaining the 13C-NMR spectrum aids in shortening relaxation times which 
consequently allows for quantitative NMR spectroscopy. Unique carbon resonances can be 
distinguished, and have been assigned by others, for short chain branches of polyethylene,15 
with the key methyl resonances from methyl, ethyl, propyl, and butyl or longer branches 
being particularly valuable. The signal at ~30 ppm in the 13C-NMR spectrum of branched 
polyethylene is due to the main CH2 groups in the polymer backbone. 
1.2.2 Metal-Free Defunctionalization  
Defunctionalization of organic functional groups is an important process in synthetic 
chemistry, particularly in the reduction of the C-O functional group to a methyl group. The 
carbonyl functionality can be reduced through a Clemmensen16 reduction, which makes use 
                                                
14 Daugulis, O.; Brookhart, M.; White, P. S. Organometallics 2002, 21, 5935.  
15 Cotts, P.; Guan, Z.; McCord, E.; McLain, S. Macromolecules 2000, 33, 6945-6952. 
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of a strong acid and amalgamated zinc, or through the complementary Wolff-Kirschner17,18 
reduction, which employs hydrazine and a strong base. These defunctionalization procedures 
require harsh conditions: high temperatures, high pressures, and strong acids or bases. The 
combination of a Lewis acid and a hydrosilane provides a milder approach for the reduction 
of carbonyl-containing compounds. 
One defunctionalization reaction that has not received significant attention is the 
conversion of C-O bonds at the alcohol oxidation state to C-H bonds, i.e. alcohols to alkanes. 
The Lewis acid trispentafluorophenylborane (B(C6F5)3) has been investigated as a catalyst in 
the mild hydrosilylative reduction of C-O bonds because of its commercial availability, 
convenient handling, and comparable Lewis acidity to BF3.19 B(C6F5)3 is advantageous over 
BF3 because it avoids problems associated with reactive B-F bonds.  Yamamoto first reduced 
primary alcohols using triethylsilane in the presence of catalytic amounts of B(C6F5)3.20 This 
was the first example of catalytic use of a Lewis acid in the reduction of alcohols. Addition 
of an equimolar amount of silane resulted in silyl-protection to quantitatively produce the 
alkyl silyl ether (with concomitant H2 evolution), while adding excess silane (3 equivalents) 
fully reduced a primary alcohol to the alkane (Scheme 1.1). Using triethylsilane, more bulky 
secondary and tertiary alcohols were not reduced and only the corresponding silyl ethers 
                                                
16 Clemmensen, E. Ber. 1914, 47, 681-687. 
 
17 Kishner, J. J. Russ. Phys. Chem. Soc. 1911, 43, 582. 
 
18 Wolff, C . Justus Liebigs Ann. Chem. 1912, 394. 86. 
 
19 Ishihara, K.; Yamamoto, H. Eur. J. Org. Chem. 1999, 3, 527. 
 
20 Gevorgyan, V.; Liu, J.; Rubin, M.; Benson, S.; Yamamoto, Y. Tetrahedron Lett. 1999, 40, 
8919-8922. 
 8 
were obtained. Cleavage of linear and cyclic primary alkyl ethers was achieved in the 
presence of a stoichiometric amount triethylsilane and catalytic amounts of B(C6F5)3 to give 
the corresponding alkane and silyl ether. Nimmagadda and McRae further expanded the 
reduction of alcohols to secondary and tertiary alcohols, though this required the use of more 
reactive hydrosilanes, such as diethylsilane or n-butylsilane.21 Further investigations by 
Yamamoto indicated that the relative reactivity of alcohols towards reduction was: primary 
>> secondary > tertiary.22  
Scheme 1.1. Treatment of a primary alcohol with HSiEt3 and catalytic amounts of B(C6F5)3.  
 
 
Inspired by the mild B(C6F5)3-reduction approach, Njardarson investigated the 
reduction of the C-O bonds in unsaturated cyclic ethers.23 First, the reduction of 2,5-
dihydrofurans, which contain two allylic ethereal C-O bonds, was studied to compare the 
impact of sterics and electronics in the reaction mechanism. Following the reduction of 2-
heptyl-2,5-dihydrofuran (Scheme 1.2), the less sterically hindered C-O bond was cleaved, 
suggesting that steric congestion does impact the selectivity of reduction. However, 
B(C6F5)3-reduction of 2-phenyl-2,5-dihydrofuran, shown in Scheme 1.3, indicates that other 
factors can influence the selectivity, for example when a cation-stabilizing group is present. 
                                                
21 Nimmagadda, R.; McRae, C. Tetrahedron Lett. 2006, 47, 5755-5758. 
 
22 Gevorgyan, V.; Rubin, M.; Benson, S.; Liu, J.; Yamamoto, Y. J. Org. Chem. 2000, 65, 
6179-6186. 
 
23 Mack, D.; Guo, B.; Njardarson, J. Chem. Commun. 2012, 48, 7844-7846. 
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The results suggest that both sterics and electronics play a role in the cleavage of the C-O 
bonds. Secondly, the B(C6F5)3-reduction of 3,6-2H-dihydropyrans was studied to compare 
the reduction of allylic vs. non-allylic C-O bonds. A range of substrates was reduced, and the 
allylic C-O bond was found to be more easily reduced over the non-allylic position in all 
cases. In the case of this class of substrates, this provides a controlled route to substituted 
homoallylic alcohols. The magnitude of this preference was demonstrated on a quaternary 
substituted allylic ether in Scheme 1.4. In this case, the more stabilized allylic position was 
preferentially reduced even though it is sterically congested. The work by Njardarson has 
shown that B(C6F5)3 with a hydrosilane can selectively reduce the C-O bond of cyclic 
unsaturated ethers without affecting the initial olefin geometry. In general, allylic/benzylic C-
O bonds will be preferentially reduced over less hindered, non-stabilized C-O bonds. It is 
proposed that the activated ether is reduced fast enough to suppress formation of a free allyl 
cation and prohibit scrambling of the initial olefin geometry. 
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Scheme 1.2. Catalytic reduction of a sterically hindered 2-heptyl-2,5-dihydrofuran C-O 
bond. 
 
Scheme 1.3. Catalytic reduction of a 2-phenyl-2,5-dihydrofuran C-O bond. 
 
Scheme 1.4. Catalytic reduction of a 3,6-2H-dihydropyran C-O bond, demonstrating the 
electronic control on the reaction. 
 
Based on the work from Yamamoto20,22, McRae21, Piers24, a catalytic cycle for the 
reduction of alcohols with B(C6F5)3 is proposed in Scheme 1.5. The first step in this reaction 
is borane activation of the Si-H bond, which is believed to commence through coordination 
of the Si-H bond of the hydrosilane to the Lewis acidic boron. Nucleophilic attack of a silyl 
ether can then occur at the silicon atom by a process that has been shown to be invertive at 
Si.25 In this case, the oxygen atom of the silyl ether acts as the nucleophile. This results in the 
generation of a disilyl oxonium ion and a borohydride species. Lastly, hydride addition 
occurs to form the reduced species. In cases where alkoxide abstraction leads to stabilized 
carbocations (e.g. oxocarbenium ions), SN1-type processes may occur.22 
                                                
24 Parks, D.; Blackwell, J.; Piers, W. J. Org. Chem. 2000, 65, 3090-3098. 
 
25 Rendler, S.; Oestreich, M. Angew. Chem. Int. Ed. 2008, 47, 5997. 
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Scheme 1.5. Proposed B(C6F5)3-catalytic cycle for the reduction of alcohols.  
 
 
The proposed borane-silane adduct was recently studied and observed by Piers and 
Tuononen.26 Up until this work, attempts to spectroscopically observe the Lewis acid/base 
adduct in solution using low temperature NMR spectroscopy failed.27 These observations 
lead to the conclusion that the equilibrium lies away from formation of the B(C6F5)3-silane 
adduct. To shift the equilibrium towards the adduct, a more Lewis acidic borane species was 
utilized. The anti-aromatic 1,2,3-tris(pentafluorophenyl)-4,5,6,7-tetrafluoro-1-boraindene is a 
stronger Lewis acid than B(C6F5)3,28 and its behavior in the presence of triethylsilane (Figure 
1.3) was investigated by UV-Vis and NMR spectroscopy. The free boraindene is 
characterized by a weak absorption at 465 nm, which is disrupted upon complexation with 
Lewis bases, as observed by a color change from red to yellow that occurs on formation of 
                                                
26 Houghton, A.; Hurmalainen, J.; Mansikkamaki, A.; Piers, W.; Tuononen, H. Nat. Chem. 
2014, 6, 983-988. 
 
27 Parks, D.; Blackwell, J.; Piers, W. J. Org. Chem. 2000, 65, 3090-3098. 
 
28 Houghton, A.; Karttunen, V.; Piers, W.; Tuononen, H. Chem. Commun. 2014, 50, 1295-
1298. 
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the borane-silane adduct. Variable temperature NMR spectroscopy experiments revealed the 
formation of the Lewis acid/base adduct. 19F-NMR analysis revealed a significant 
perturbation in the chemical shift of the fluorine atom that is ortho to the boraindene boron 
atom. Cooling the sample also revealed an upfield shift for the Si-H resonance in the 1H-
NMR spectrum, as expected for a Si-H…B bridge. A crystal structure of the boraindene-
silane adduct was obtained providing further evidence for the proposed Si-H…B bridge. 
 
Figure 1.3. Lewis acid/base adduct formed between 1,2,3-tris(pentafluorophenyl)-4,5,6,7-
tetrafluoro-1-boraindene and triethylsilane. 
 
Gagné and coworkers demonstrated the use of B(C6F5)3 to catalyze the hydrosilylative 
reduction of monosaccharides and polysaccharides into hydrocarbons.29 Moreover, the 
reaction conditions were tuned to selectively deoxygenate glucose (Scheme 1.6). These 
reactions were monitored using 13C NMR spectroscopy, as it allowed the disappearance of C-
O bonds to be easily detected. For all substrates tested, complete deoxygenation was 
achieved when diethylsilane was selected as the hydride source.  It was also noted that 
depending on the identity of the sugar substrate, the relative yields of alkane and alkene 
products was variable. For instance, the deoxygenation of 1-deoxyglucose led to >60% of the 
alkyl-shifted products, 2-methyl and 3-methylpentane. By contrast, the ring-opened sugar 
glucitol only provides <15% of the production distribution in the branched form. The 
                                                
29 Adduci, L.; McLaughlin, M.; Bender, T.; Becker, J.; Gagné, M. Angew. Chem. Int. Ed. 
2014, 53, 1646-1649. 
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generation of branched products was interpreted as likely reflecting the formation of cationic-
intermediates in the deoxygenation sequence. 
Scheme 1.6. B(C6F5)3-catalyzed hydrosilylative deoxygenation of glucose into hexane and 
hexene isomers. 
 
When a tertiary silane (dimethylethylsilane) was selected as the reducing agent, the reaction 
rate and yield were significantly reduced, which is likely a reflection of the larger steric 
congestion of the bulkier silane. For example, the reduction of Me2EtSi-protected glucitol 
with dimethylethylsilane yields only partial deoxygenation even after a reaction time of 1 
week.  
1.2.3 Research Objectives 
While inexpensive methods to synthesize branched polyolefins exist, the purpose of 
this research was to apply the B(C6F5)3-catalyzed hydrosilylative deoxygenation methods to 
commercially available linear polyols determine if, and to what extent, branched polymer 
structures would ensue, in analogy to the formation of branched hexane. Initial work focused 
on deoxygenating commercially available linear polyols (of high MW), which were 
demonstrated to deoxygenate in a process that produces highly branched polyolefins with 
unique microstructures (Chapter 2). The chemistry was then applied to an industrially 
relevant triblock polymer as a means to synthesize a material containing blocks arranged in a 
linear-branched-linear architecture. Such materials display interesting phase separation 
properties (Chapter 3). 
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1.3  Nanoscale Coordination Polymers for Anticancer Drug Delivery 
1.3.1 Nanoscale Coordination Polymers 
Coordination polymers, also known as metal organic frameworks (MOFs), are 
inorganic compounds containing polymerized metal-ligand networks. The structure of 
coordination polymers is composed of metal ions connected to polydentate bridging ligands 
(Figure 1.4). The composition of the coordination can be easily tuned by simply changing the 
metal ion or the bridging ligand. The highly tunable nature of the material allows for 
different structures to be synthesized.  
 
Figure 1.4. Self-assembly of metal ion and bridging ligand to form a metal-ligand network, 
known as a coordination polymer. 
 
Published in 1960 by John Bailar, the first coordination polymer contained polymeric 
Schiff bases coordinated to various metal ions.30 Extensive research has since been 
conducted on the crystalline network form of various coordination polymers, yet the first 
nanoscale coordination polymer (NCP) was not demonstrated until 2005.31 The Mirkin group 
demonstrated that addition of an initiation solvent to an aqueous solution of metal ions and 
metalloligands resulted in spontaneous precipitation of spherical NCPs. The NCPs consisted 
                                                
30 Goodwin, H.; Bailar, J. J. Am. Chem. Soc. 1961, 83, 2467-2471. 
 
31 Oh, M.; Mirkin, C. Nature 2005, 438, 651-654. 
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of a carboxylate-functionalized binapthyl bis-metallo-tridentate Schiff base units coordinated 
to a metal ion (either Zn2+, Cu2+, or Ni2+) through the carboxylate functionalities. By adding a 
nonpolar solvent to the polar precursor solution, precipitation occurred due to the poor 
solubility of the NCPs.  
1.3.2 Nanoscale Coordination Polymers in Drug Delivery 
Since the initial discovery of NCPs, these materials have been investigated for use in 
drug delivery. Conventional small molecule therapeutics are limited by their rapid clearance 
and nonspecific distribution in the body, which leads to high doses and adverse side effects.32 
Incorporation of the small molecule drug into a nanomaterial provides a route to overcome 
the side effects and to increase the circulation time. Considerable research is being conducted 
in designing nanoparticles that are capable of controllable release of an active drug at a 
targeted area of interest and selective delivery of the drug to the target tumor sites.33 Many 
nanoscale systems have been shown to load and release drugs; these systems include: 
liposomes34,35, polymer micelles36, dendrimers37, inorganic particles38,39, and mesoporous 
                                                
32 Davis, M.; Chen, Z.; Shin, D. Nat. Rev. Drug Discov. 2008, 7, 771. 
 
33 Peer, D.; Karp, J.; Hong, S.; Farokhzad, O.; Margalit, R.; Langer, R. Nat. Nanotech. 2007, 
2, 751-760. 
 
34 Allen, T.; Cullis, P. Adv. Drug Del. Rev. 2013, 65, 36-48. 
 
35 Torchilin, V. Nat. Rev. Drug Discov. 2005, 4, 145-160. 
 
36 Siddik, Z.; Jones, M.; Boxall, F.; Harrap, K. Cancer Chemother. Pharmacol. 1988, 21, 19-
24. 
 
37 Bosman, A.; Janssen, H.; Meijer, E. Chem. Rev. 1999, 99, 1665-1688. 
 
38 Cobley, C.; Chen, J.; Cho, E.; Wang, L.; Xia, Y. Chem. Soc. Rev. 2011, 40, 44-56. 
 
39 Kim, J.; Piao, Y.; Hyeon, T. Chem. Soc. Rev. 2009, 38, 372-390.  
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silica.40 Through extensive research in this area, successful translation into clinical studies 
has been achieved for few nanocarrier systems, such as doxorubicin (Doxil) and 
daunorubicin (Daunoxome).  
Passive targeting of nanoparticles to the tumor region occurs due to the enhanced 
permeability and retention (EPR) effect (Figure 1.5).41 Newly formed tumor vessels are 
abnormal in form and architecture, leading to large fenestrations in which macromolecules 
can escape through. The EPR effect is known as passive targeting because nanoparticles are 
unable to penetrate through the tight junctions of normal blood vessels. Furthermore, the 
nanoparticles are retained in the tumor region due to poor lymphatic drainage. Over time, the 
concentration of nanoparticles in the tumor site can build up due to the lack of effective 
drainage. 
 
Figure 1.5. The enhanced permeability and retention (EPR) effect which leads to passive 
tumor targeting by nanoparticles. Illustration provided by Demin Liu.  
 
                                                
40 Lu, J.; Liong, M.; Zink, J.; Tamanoi, F. Small 2007, 3, 1341-1346. 
 
41 Greish, K. Methods Mol. Biol. 2010, 624, 25-37. 
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Additionally, the surface of nanoparticles can be coated or functionalized with many 
different types of molecules for therapeutic applications. For instance, by incorporating 
poly(ethylene glycol) (PEG) onto the surface, nonspecific adsorption of proteins onto the 
nanoparticles can be minimized, increasing the blood circulation time.42 The hydrophilic 
nature of PEG attracts water molecules that shield the particle from protein adsorption. In 
other cases, coating nanocarriers with a lipid bilayer coating aids in creating a neutral surface 
charge to minimize nonspecific protein interactions. PEGylated liposomes can be utilized to 
coat the nanoparticles in a neutral bilayer and to increase the blood circulation time by 
preventing protein interaction with the nanoparticle surface. Also, pegylated liposomes are 
slow to degrade, resulting in a slow, sustained release of drug from the interior. Up until 
release, the drug is inert due to its entrapment. Alternatively, molecules can be directly 
attached to the particle surface to serve as targeting functionalities. Incorporation of a 
targeting molecule can play a role in cell uptake by specific cell types. Various molecules, 
including nucleic acid aptamers, antibodies, and small organic compounds, have been used to 
achieve active targeting of cancer cells. Introduction of functional groups (such as 
carboxylates) onto these targeting molecules allow for conjugation onto the nanoparticle.  
The Lin group has set precedence in the development of NCPs for effective 
anticancer therapy. Using NCPs as an alternative approach to other nanocarriers provides 
many advantages due to the properties and characteristics of coordination polymers. NCPs 
can combine the advantages of both inorganic and organic nanoparticles to exhibit 
                                                
42 Jokers, J.; Lobovkina, T.; Zare, R.; Gambhir, S. Nanomed. 2011, 6, 715-728. 
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compositional tunability, biodegradability, high drug loadings,43 surface functionalization, 
and well-defined morphologies.44,45 Incorporation of an anticancer therapeutic into the 
framework of the NCP allows for exceptionally high drug loadings. Secondly, adjusting the 
synthetic conditions can modify the composition, shape, and size of the NCPs. Additionally, 
the relatively labile metal-ligand bond makes NCPs biodegradable. 
1.3.3 Initial Drug Delivery NCPs 
Direct incorporation of a drug into a NCP framework can be achieved through use of 
the active agent as the bridging ligand. A cisplatin prodrug. disuccinatocisplatin (c,c,t-
[PtCl2(NH3)2(O2CCH2CH2CO2H)2]), was designed for use in a Tb(III) NCP.46 Dynamic light 
scattering (DLS) measured the hydrodynamic diameter of the NCPs to be ~58.3 nm in size. 
To increase the stability of the coordination polymer, the NCPs were encapsulated in silica. 
The resulting drug release exhibited a t1/2 of 9 hours after silica coating, whereas the bare 
NCPs had a t1/2 equal to 1 hour. Active targeting was achieved by functionalizing the Tb-
based NCP surface with c(RGDfk), a peptide that targets the αvβ3 integrin overexpressed on 
certain cancer cell lines. The targeted NCPs displayed a higher cytotoxicity than cisplatin 
(IC50= 9.7 µM and 13.0 µM, respectively) when tested against HT-29 human colorectal 
adenocarcinoma cells. The nontargeted version did not display any cytotoxic effects against 
                                                
43 Kim, J.; Piao, Y.; Hyeon, T. Chem. Soc. Rev. 2009, 38, 372. 
 
44 Champion, J.; Mitragotri, S. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 4930. 
 
45 Yavuz, M.; Cheng, Y.; Chen, J.; Cobley, C.; Zhang, Q.; Rycenga, M.; Xie, J.; Kim, C.; 
Song, K.; Schwartz, A.; Wang, L.; Xia, Y. Nat. Mater. 2009, 8, 935. 
 
46 Rieter, W.; Pott, K.; Taylor, K.; Lin, W. J. Am. Chem. Soc. 2008, 130, 11584. 
 
 19 
this cell line. The improved cytotoxity of the c(RGDfk)-targeted NCPs suggest that active 
targeting can be achieved. 
 Another method to incorporate small molecules drugs into NCPs is through post-
functionalization of the bridging ligands. Lin and coworkers synthesized Fe(III)-carboxylate 
NCPs with a MIL-101 structure by solvothermal methods (~200 nm in diameter by DLS).47 
Covalent attachment of biologically relevant cargoes was achieved without altering the NCP 
structure. The NCP was successfully post-synthetically modified with an optical imaging dye 
(BODIPY) and a cisplatin prodrug. UV-Vis spectroscopy confirmed a BODIPY loading of 
up to 12 wt%, and ICP-MS confirmed a cisplatin loading of 13 wt%. Confocal microscopy 
revealed that HT-29 cells internalized the BODIPY-loaded NCPs. Silica coating was again 
used to increase the stability of the NCP system, which increased the t1/2 from 1 hour to 14 
hours. Post-functionalization with both an imaging agent and a therapeutic agent suggest that 
NCPs can be developed for theranostic applications. 
1.3.4 Stabilization of NCPs 
Although silica coating of NCPs aids in controlled release of the drug, the previously 
reported NCPs were not stable under physiological conditions. Therefore, alternative NCP 
systems encapsulated in a lipid bilayer were synthesized. First, NCPs were used to deliver 
nitrogen-containing bisphosphonates (N-BPs) to cancer cells.48 The structure of two different 
N-BPs, zoledronic acid and pamidronic acid, are shown in Figure 1.6. Currently used to treat 
osteoporosis, N-BPs are not effective anticancer drugs due to their high affinity towards bone 
                                                
47 Taylor-Pashow, T.; Della Rocca, J.; Xie, Z.; Tran, S.; Lin, W. J. Am. Chem. Soc. 2009, 131, 
14261-14263. 
 
48 Liu, D.; Kramer, S.; Huxford-Phillips, R.; Wang, S.; Della Rocca, J.; Lin, W. Chem. 
Commun. 2012, 48, 2668-2670. 
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absorption. By incorporating N-BPs into NCPs, targeted delivery of the drugs to cancer cells 
can be achieved. Both zoledronate and pamidronate were incorporated into the framework of 
NCPs through coordination to Ca2+ ions. The as-synthesized NCPs rapidly decomposed in 
solution (t1/2 = 6.3 h for pamidronate NCP). To control the release of the N-BPs, the surface 
of the NCPs was coated with single lipid bilayers. Following lipid coating, the drug release 
kinetics demonstrated a significant increase in the in vitro circulation half-life (t1/2 = 20.1 h 
for pamidronate NCP). Therefore, it was concluded that the presence of the single lipid 
bilayer significantly stabilized the NCP systems. 
 
Figure 1.6. Structure of two nitrogen-containing bisphosphonates, zoledronic acid and 
pamidronic acid. 
 
More recently, the self-assembly of two zinc bisphosphonate NCPs containing 
approximately 48 wt% cisplatin prodrug or 45 wt% oxaliplatin prodrug was reported.49 These 
NCPs possess hydrodynamic volumes in the range of 20-30 nm as determined by DLS. The 
NCPs were surrounded by a lipid bilayer and further PEGylated to increase the circulation 
times. Following PEGylation, the hydrodynamic diameters of the NCPs increased to 40-45 
nm, indicating the presence of the lipid bilayer on the particle surface. In vitro stability 
studies revealed that the near-neutral surface charge of these systems minimized nonspecific 
protein interactions suggesting that uptake by the MPS can effectively be avoided. 
Additionally, no premature drug release was observed from these NCPs prior to being placed 
into a reducing environment similar to that of the tumor site. This suggests that the NCPs can 
                                                
49 Liu, D.; Poon, C.; Lu, K.; He, C.; Lin, W. Nat. Commun. 2014, 5, 4182.  
OH NH2PHO
HO
O
P OH
OH
O
N
N
OH
PHO
HO O
P
OHHO
O
zoledronic acidpamidronic acid
 21 
circulate the body with minimal drug release, but upon arrival at the tumor site, the active 
agent can be released. Further, the selective delivery of the zinc-based NCPs to solid tumors 
was achieved in several different mouse models.  
1.3.5 Research Objectives 
  While cisplatin is an effective anticancer therapeutic, this research aimed to minimize 
the adverse side effects from the small molecule agent by incorporating a cisplatin prodrug 
into two new NCP platforms containing either calcium or manganese (Chapter 4). Calcium is 
a biocompatible metal making it a desirable metal for use in drug delivery NCPs. The first 
system used calcium as the metal ion and a cisplatin prodrug as the bridging ligand to form 
the NCP framework. The second system incorporated manganese into the cisplatin-based 
NCP to synthesize a theranostic agent. In vitro stability and cytotoxic assays were conducted 
on both particle systems.  
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 B(C6F5)3-CATALYZED HYDROSILYLATIVE DEOXYGENATION OF Chapter 2.
POLYOLS TO FORM HIGHLY BRANCHED STRUCTURES 
2.1 Introduction 
The synthesis of branched polyolefins for industrial applications involves 
polymerization of olefin monomers using either free radical initiators or metal catalysts.1 In 
contrast to free radical methods, coordination catalysts have demonstrated the ability to 
exercise significantly greater control of the polymer microstructure.50 Depending on the 
catalyst selected, control over the both the regiochemistry and stereochemistry of monomer 
enchainment can be achieved, which provides for polymers with variable properties.  The 
microstructure and molecular weight of a polymer controls the properties of the bulk 
material, which consequently influences the applications for which it may be used.  
We are interested in developing alternative methods to synthesize branched 
polyolefins through defunctionalization of linear, high MW polyols. The Lewis acid 
trispentafluorophenylborane (B(C6F5)3) has previously been used as a catalyst in the mild 
hydrosilylative reduction of C-O bonds.20,22, 21,24 Typically, a hydrosilane, such as 
diethylsilane, is used as the hydride source in the reduction. Our group has utilized this 
chemistry to affect the deoxygenation of carbohydrates as a possible approach to biomass 
conversion to fuels.29 When diethylsilane was combined with the B(C6F5)3 catalyst, an 
aggressive reduction of glucose ensues to generate a mixture of products wherein hexane and 
                                                
50 Domski, G.; Rose, J.; Coates, G.; Bolig, A.; Brookhart, M. Prog. Polym. Sci. 2007, 32, 30-
92. 
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hexene isomers  were observed, the former being dominant. The formation of branched 
products (predominantly 2-methylpentane and 3-methylpentane) indicates that elimination 
and alkyl shifting occurs during the deoxygenation process.  Interestingly, the product 
distribution was dependent on the silane and protecting group used for the glucose OH 
groups. 
In this study, we applied the B(C6F5)3-catalyzed hydrosilylative deoxygenation to 
linear polyols to explore how reduction would affect the structure of the reduced 
hydrocarbon polymer. The reduction protocol leads to completely deoxygenated, highly 
branched polyolefins. We investigated the effect of the silane and protecting group on the 
branching and amount of elimination that occurs during the deoxygenation. Both 1H and 13C 
NMR spectroscopy were used as the primary methods to study the polymer structures post-
deoxygenation. 
2.2  Experimental 
2.2.1 Materials 
The deoxygenation reactions were performed inside a Vacuum Atmospheres 
glovebox under an argon atmosphere. All chemicals were purchased from Sigma Aldrich or 
Fischer Scientific unless otherwise noted. Tris(pentafluorophenyl) borane was purchased 
from Gelest, Inc. Methylene chloride was degassed via three freeze-pump-thaw cycles and 
dried over 4Å molecular sieves prior to use. Diethylsilane was dried over 4Å molecular 
sieves prior to use. Poly(vinyl alcohol) was purchased from Sigma Aldrich with a MW of 9-
10,000. 
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2.2.2 Instrumentation and Analysis 
NMR spectra were recorded using a Bruker Avance III spectrometer equipped with a 
cryoprobe operating at 600 MHz (1H) or 150 MHz (13C). NMR chemical shifts are reported 
in ppm and internally referenced to residual proton peaks (1H) or the 13C resonances of the 
deuterated solvent (13C). All NMR spectra were recorded in CDCl3 or CD2Cl2. For 13C-NMR 
spectroscopy, chromium(III) acetate (Cr(acac)3) was added as a relaxation agent to all 
polymer samples prior to collecting spectra (d1 = 1 s).  
Gel permeation chromatography (GPC) was performed using an Agilent Tchnologies 
1260 Infinity separation module equipped with two Agilent 3 µm MIXED-E 30x7.5mm 
column and a Wyatt Optilab T-Rex refractive index detector. Polymer samples were prepared 
in HPLC grade tetrahydrofuran and filtered before injection. Tetrahydrofuran was used as the 
eluent with a flow rate of 1.0 mL/min at 25 °C. Retention times were calibrated against 
narrow molecular weight polystyrene standards. 
2.2.3 Hydroboration-Oxidation of Polybutadiene 
 
Polybutadiene was hydroborated with borane reagents followed by oxidation using a 
procedure similar to that previously reported.51 A typical hydroboration-oxidation sequence 
was done as following: 0.5 g of polymer was combined with 50 mL of 0.5 M 9-9-
borabicyclo[3.3.1]nonane (9-BBN)  in THF under an N2 atmosphere. The reaction was 
stirred for 3 days at room temperature. To the resulting solution, a mixture of NaOH (3.0 M, 
2.0 mL) and aqueous H2O2 (30%, 2.0 mL) was added at 0 °C. The reaction mixture was 
                                                
51 Kino, T.; Tomita, I. Polymer Bulletin 2005, 55, 251-258. 
OH
25 
allowed to stir at room temperature overnight. The mixture was dialyzed against 1:1 MeOH: 
water for 5 hours, or until pH was neutral. The MeOH: water was changed hourly. The 
reaction mixture was then removed from the dialysis tubing, the insoluble fraction was 
removed by filtration, and the soluble fraction was rotovapped to isolate the polyol (PBD-
OH, 52% yield). 1H NMR (600 MHz, Chloroform-d) δ 3.81 – 3.78 (broad, m, 1H), 1.90 – 
1.21 (broad, m, 6H). 13C-NMR (600 MHz, Chloroform-d) δ 71.90, 36.43, 31.53, 20.17. 
2.2.4 Protection of Polyols 
PVA and hydroxylated-polybutadiene were protected with different silanes using the 
following procedure: unprotected polymer (0.5 g) was dissolved in 20 mL pyridine and 0.05 
moles of chlorosilane were added. The reaction was stirred for 3-4 days before workup. To 
quench the silane, 50 mL of water was added. The protected polymer was extracted into 
diethyl ether (3 x 50 mL). The ether layers were combined and washed with water (3 x 50 
mL), brine (3 x 50 mL), and then dried over MgSO4. The solvent was removed by rotary 
evaporation. The product was triturated with toluene to remove any remaining pyridine and 
was dried on the vacuum line overnight. The materials were isolated as viscous oils. 
 
PVA-TMS: 90% yield; 1H NMR (600 MHz, Methylene chloride-d2) δ 3.87 (broad, 
1H), 1.99*, 1.59 (broad, 2H), 0.12 (broad, 9H). 13C-NMR (600 MHz, Methylene chloride-d2) 
δ 170.99*, 67.74, 47.50, 21.63*, 1.63. *Indicates minor peaks in spectrum due to 
unhydrolyzed poly(vinyl acetate) in starting material.  
 
 
OTMS
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PVA-SiMe2Et: 1H NMR (600 MHz, Chloroform-d) δ 3.85 (broad, 1H), 1.99*, 1.56 
(broad, 2H), 0.92 (3H), 0.57 (2H), 0.09 (6H). 13C-NMR (600 MHz, Chloroform-d) δ 170.49*, 
67.03, 46.90, 21.16*, 9.45, 7.15, 1.19. *Indicates minor peaks in spectrum due to 
unhydrolyzed poly(vinyl acetate) in starting material. 
 
PVA-TES: 1H NMR (600 MHz, Chloroform-d) δ 3.86 (broad, 1H), 1.98*, 1.55 
(broad, 2H), 0.93 (9H), 0.54 (6H). 13C-NMR (600 MHz, Chloroform-d) δ 170.57*, 67.07, 
46.94, 21.03*, 9.45, 6.64, 5.88. *Indicates minor peaks in spectrum due to unhydrolyzed 
poly(vinyl acetate) in starting material. 
 
PBD-OTMS: 1H NMR (600 MHz, Chloroform-d) δ 3.78 – 3.66 (m, 1H), 1.83 – 1.50 
(m, 4H), 1.49 – 1.28 (m, 2H), 0.17 – 0.05 (s, 9H). 13C-NMR (600 MHz, Chloroform-d) δ 
72.07, 36.47, 20.07, 0.04. 
 
PBD-OSiMe2Et: 1H NMR (600 MHz, Chloroform-d) δ 3.71 (m, 1H), 1.83 – 1.57 (m, 
4H), 1.38 – 1.32 (m, 2H), 0.91 (t, 3H), 0.54 (q, 2H), 0.04 (s, 6H). 13C-NMR (600 MHz, 
Chloroform-d) δ 72.08, 36.56, 20.16, 8.38, 6.72, 2.24. 
 
 
OSiMe2Et
OTES
OTMS
OSiMe2Et
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2.2.5 General Deoxygenation Procedure 
In a nitrogen-filled glovebox, silyl-protected polymer (50 mg) and B(C6F5)3 (5 mol% 
relative to monomer) was dissolved in 0.25 mL CD2Cl2 or CH2Cl2. Then, 0.25 mL of silane 
(diethylsilane, dimethylethlsilane, or triethylsilane) was added. The solution was immediately 
capped with a vented cap and swirled. After gas evolution subsided, the reaction mixture was 
transferred to a septum-capped NMR tube and removed from the glovebox to continue 
reacting for 48 h at 35 °C. At this point, in situ NMR spectra were obtained if desired.  
2.2.6 General Silane Removal Procedure 
To remove excess silane and silyl ether from the deoxygenation reaction, the reaction 
mixture was added to a 15-mL plastic centrifuge tube. To the centrifuge tube, 0.80 mL of 
pyridine-HF was added. The reaction mixture was treated with pyridine-HF for 24 h. Silica 
was then added to remove any excess HF present. The silica was isolated by vacuum 
filtration, and the filtrate was rotovapped to yield the branched polyolefin. 
2.2.7 General Hydrogenation Procedure 
The branched polyolefin was dissolved in 2.0 mL of CH2Cl2 and transferred to a 
Fisher porter vessel. Wilkinson’s catalyst (1 mol%) was added, and the vessel was put under 
40 psi of H2. The reaction was allowed to stir at 40 °C for two days. The catalyst was 
removed by vacuum filtering over a silica plug, which was washed with 10 mL of CH2Cl2. 
The solvent was then removed by rotary evaporation to yield the hydrogenated, branched 
polyolefin. 
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2.3 Results and Discussion 
2.3.1 Synthesis and Deoxygenation of TMS-PVA 
During the deoxygenation process, the reaction conditions cause any of the free 
alcohols to become silylated, though the relative rates of OH silylation versus -OSiR3 
deoxygenation are difficult to assess. To aid in studying the deoxygenation and to increase 
the solubility of the polymer, poly(vinyl alcohol) (PVA, MW=9-10,000) was preprotected as 
a silyl ether. As shown in Scheme 2.1, this was accomplished with TMS-Cl in pyridine; 48 h 
reaction times ensured complete formation of silyl ethers, and the desired product was 
isolated in 90% yield. 
Scheme 2.1. TMS-Protection of Poly(vinyl Alcohol). 
 
Use of a catalytic amount of commercially available B(C6F5)3 with diethylsilane as 
the reducing agent caused complete deoxygenation of PVA-TMS to occur (35 °C, 48 h, 
Scheme 2.2) as ascertained by NMR spectroscopy and gel permeation chromatography 
(GPC). Since the theoretical mass loss for the conversion of PVA-TMS to PE is 76%, GPC 
was used to check this loss of mass. This technique separates polymers based on size with 
high molecular weight polymers eluting first. Figure 2.1 shows the GPC chromatogram of 
TMS-protected PVA and the corresponding deoxygenated product. Qualitatively, the starting 
material elutes at a shorter retention time indicating that the product is indeed of lower 
molecular weight. The broad MW distribution additionally suggests that the deoxygenated 
polyolefin may have suffered chain scission during deoxygenation, may have become more 
heterogenous, and/or may have become branched. 
OH OTMSTMS-Cl
Pyridine
35 °C, 48 hn n
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Scheme 2.2. Deoxygenation of TMS-PVA with B(C6F5)3 and diethylsilane. 
 
 
 
Figure 2.1. GPC chromatogram of the starting material (TMS-PVA, black) compared to the 
deoxygenated product (blue) confirming loss of mass following deoxygenation. 
 
Particularly helpful was 13C-NMR analysis as this enabled the disappearance of the 
C-O bond to be followed. To perform quantitative 13C-NMR analysis, spectra were obtained 
by dissolving the polymer sample in a 0.05M solution of Cr(acac)3 (relaxation agent) in 
CDCl3 or CD2Cl2, and a 1 s relaxation delay between scans was used . 1H gated decoupling 
was performed to reduce NOE enhancement. The two characteristic peaks of the starting 
material at 67 (carbinol CHOSiR3) and 47 ppm (CH2) shift to an envelope of peaks upfield of 
45 ppm. Figure 2.2 compares the 13C-NMR spectrum of the starting material (TMS-PVA) to 
the in situ derived deoxygenation reaction. Based on the in situ NMR spectrum, complete 
deoxygenation was achieved during this period of time, at least to the detection limit of the 
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spectra. The presence of excess silane used for the reduction and the R3Si-O-SiR3 
complicates 13C-NMR analysis of the deoxygenated polymer structure. These interferents 
were removed from the deoxygenated polymer by treating with pyridine-HF, which breaks 
the Si-O bonds through formation of the stronger Si-F bond.52 Excess silica gel was added to 
quench any remaining HF. The deoxygenated polymer was isolated by filtration, and the 
solvent was removed.  
                                                
52 Wuts, P.; Greene, T. Protection for the Hydroxyl Group, Including 1,2- and 1,3-Diols. In 
Protective Groups in Organic Synthesis, 4th ed.; John Wiley & Sons, Inc.: Hoboken, New 
Jersey, 2007; 16-366. 
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Figure 2.2. 13C-NMR spectra (in CD2Cl2) of PVA-TMS (top) and in situ deoxygenation of 
PVA-TMS (bottom). 
 
NMR analysis (Figure 2.3) was used to study the purified deoxygenated polymer 
structure. The 13C-NMR spectrum shows a complex, highly branched polyolefin. The peak at 
68 ppm indicates that this sample remained partially oxygenated. Several peaks were 
observed in the 120-150 ppm region, indicative of alkene groups and the likelihood of 
elimination occurring during the deoxygenation process.53 Most characteristic were the many 
peaks observed in the 10-50 ppm region of the spectrum, consistent with a highly branched 
                                                
53 Eğe, S. Elimination Reactions. In Organic Chemistry: Structure and Reactivity, 5th ed.; 
Houghton Mifflin: Boston, 2004; 264-271. 
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microstructure post-deoxygenation. Since the starting polyol is a linear structure, it appears 
that the deoxygenation is accompanied by significant alkyl shifting, perhaps reasonably 
suggesting the intermediacy of carbocations.54 For the reduction of TMS-PVA, 1H-NMR 
spectroscopy was used to quantify the degree of branching and elimination in the resulting 
product. Modifications of the previously reported formula for calculating the number of 
branches in a polyethylene sample14, Equation 2.1 and Equation 2.2 were used to estimate 
both the branch and elimination number. It is important to note that Equation 2.2 does not 
account for the presence of tri- and tetra- substituted alkenes in the elimination calculation, 
which consequently underestimates the number of alkenes per 1000 C in the product 
polymer. The expectation is that these would represent low probability events given the 
linear nature of the starting polymer, but it does represent an uncertainty. The branch 
numbers for the polyolefin were determined from the ratio of the integration of methyl 
groups to the integration of total carbons (methyl + methylene + methine + allyl + alkene) in 
the 1H-NMR spectrum. Integration of the methyl 1H resonances with respect to the total 
resonances and applying the formula in Equation 2.2 gave the notably high average degree of 
branching of 210 + 35 per 1000 C (Table 2.2, Entry 1), which suggests that nearly one out of 
every two C2 “ethylene” units contains a branch. Similarly, the number of alkenes per 1000 C 
can be determined by taking a ratio of the alkenes to the total carbon integration. This 
analysis suggested that the deoxygenated polyolefin possessed an average of around 17 
alkenes per 1000 C (1 alkene = 2 alkene carbons). 
                                                
54 Eğe, S. Rearrangements of Carbocations. In Organic Chemistry: Structure and Reactivity, 
5th ed.; Houghton Mifflin: Boston, 2004; 289-291. 
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Figure 2.3. 13C-NMR spectrum of partially deoxygenated TMS-PVA (in CD2Cl2) after 
treatment with pyridine-HF. The presence of peaks between 120-140 ppm indicates the 
likelihood of elimination occurring, whereas peaks between 15-50 ppm indicates the 
likelihood of rearrangement occurring during the deoxygenation reaction. 
 
Equation 2.1. 
 
Equation 2.2. 
 
An example NMR analysis to determine the number of branches and alkenes present 
is shown below. The 1H-NMR spectrum shown below (Figure 2.4) is following 
deoxygenation (with borane and SiEt2H2) and pyridine-HF treatment of TMS-PVA. The 
integration values for each unique proton resonance are presented in Table 2.1.  
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Figure 2.4. 1H-NMR spectrum of deoxygenated, non-hydrogenated TMS-PVA (in CD2Cl2) 
after treatment with pyridine-HF. Analysis of the proton integrations using Equation 2.1 and 
Equation 2.2 determined a branch number of 210 and an alkene number of 30 (per 1000 C). 
 
Table 2.1. 1H-NMR relative integration values for each unique proton resonance in the 
deoxygenated polymer produced from the reduction of TMS-PVA with borane and 
diethylsilane. 
Proton Type Methyl Methylene Methine Allyl Alkene 
Relative Integration 3.15 7.60 1.23 1.00 0.34 
 
Calculation 1. Determination of branch number for the polymer produced from 
deoxygenation of PVA-TMS. 
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#!!"#$%ℎ!"1000! = 3.1532×0.34+ 1.23+ 7.60+ 3.152 !1000 
#!!"#$%ℎ!"1000! = 3.15312.662 !1000 = 1.056.33 !1000 #!!"#$%ℎ!"1000! = 167! ≈ 170 
Calculation 2. Determination of alkene number for the polymer produced from 
deoxygenation of PVA-TMS. 
 #!!"#$%$&1000! = 0.3422×0.34+ 1.23+ 7.60+ 3.152 !1000 #!!"#$%$&1000! = 0.34212.662 !1000 = 0.176.33 #!!"#$%$&1000! = 27 
Even at this stage, the polyolefin structure was too complex to analyze the branching 
structure present by 13C NMR spectroscopy. The sample was further simplified by exhaustive 
hydrogenation of all alkenes using 1 mol% of freshly prepared Wilkinson’s catalyst at 40 psi 
hydrogen and 40 °C (2 days). A fresh preparation of Wilkinson’s catalyst was key to 
achieving complete reduction. To remove the catalyst, the mixture was passed through a 
silica plug eluting with hexanes, and the polymer was isolated by evaporation of the solvent. 
Figure 2.5 displays the 13C-NMR spectra of deoxygenated TMS-PVA before and after 
hydrogenation with Wilkinson’s catalyst, which shows exhaustive hydrogenation was 
# Alkenes
1000C =
CHalkene
2
(2×CHalkene +CH +CH2 +CH3)
2
×1000
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achieved as evidenced by the disappearance of alkene peaks at 120-140 ppm. The branch 
number on the hydrogenated polymer was again calculated using Equation 2.2 following 
hydrogenation, and no change in branch number was observed, confirming that the modified 
equation provides a reasonable branch number estimation. For convenience, all branch 
numbers in this chapter were thus calculated prior to hydrogenation of the polymer. 
 
Figure 2.5. 13C-NMR spectrum of deoxygenated TMS-PVA after pyridine-HF treatment: 
before (top) and after (bottom) hydrogenation with Wilkinson’s catalyst. Following 
hydrogenation, the sample no longer appears to contain alkenes, which are characterized by 
peaks at 120-140 ppm. 
 
 Figure 2.6 shows the 13C-NMR spectrum obtained following exhaustive 
hydrogenation with Wilkinson’s catalyst. Based on previous literature, the carbon resonances 
can be assigned to unique types of branches.55,56,57 The peak at 30 ppm represents the 
                                                
55 Gottfried, A.; Brookhart, M. Macromolecules 2003, 36, 3085-3100. 
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methylenes in the middle of a long, straight chain (at least 4 methylene groups on each side). 
The other carbon resonances, such as methines at a branch point, have been assigned by 
Brookhart and the DuPont group.57 Comparison of the hydrogenated polyalkane to 
previously reported branched polyethylene samples shows a number of structural similarities, 
and some differences. The deoxygenated material contains methyl, propyl, butyl and longer 
branches, but does not apparently contain ethyl branches, which are characterized by a 
resonance at ~11 ppm. In contrast to the branched polymers reported by Brookhart for Ni-
catalyzed ethylene polymerization, the methyl peaks (20 ppm) in the present case appear to 
be more complex. Notably, the peak(s) at 46 ppm, which is characteristic of a methylene 
between two branch points, is significant in the present samples, but completely absent in the 
Ni-derived branched polyethylene.57,58 
                                                
56 Prasad, J.; Rao, P.; Garg, V. Eur. Polym J. 1991, 27, 251-254. 
 
57 McCord, E.; McLain, S.; Nelson, L.; Ittel, S.; Tempel, D.; Chris, K.; Johnson, L.; 
Brookhart, M. Macromolecules 2007, 40, 410-420. 
 
58 Hsieh, E.; Randall, J. Macromolecules 1982, 15, 1402-1406. 
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Figure 2.6. 13C-NMR spectrum of deoxygenated TMS-PVA following hydrogenation. 
Labels are marked as Cx, where x is the chain length. EOC is end of chain; 2EOC is the 
second carbon from the end of the chain. The Greek letters indicate how far from a branch 
point each methylene is. 
 
The deoxygenation of poly(vinyl alcohol) samples by a combination of borane and 
diethylsilane leads to complete deoxygenation and the introduction of significant branching 
in the resulting polymer. Although this reactivity parallels observations on the conversion of 
glucose to hexanes, the amount of branching was surprisingly high.  
2.3.2 Effect of Silane and Protecting Group 
Previously, the Gagné lab demonstrated that both the protecting group and the silane 
affect the selectivity and reactivity in glucose deoxygenation chemistry.29 For instance, the 
rate and selectivity of the reduction of Me2EtSi-protected glucitol were affected when the 
hydrosilane was changed from diethylsilane to dimethylethylsilane (Figure 2.6), indicating a 
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significant steric effect for this specific experiment. In the deoxygenation of Me2EtSi-
protected glucitol with dimethylethylsilane, only partial consumption of the C-O bonds was 
observed even after reaction times of 1 week. Under these reaction conditions, reduction of 
primary C-O bonds was kinetically favored. When diethylsilane was used as the hydrosilane, 
complete reduction of glucitol occurred within 2 h.29 
 
Figure 2.7. Reduction of Me2EtSi-protected glucitol with different hydrosilanes, 
demonstrating that the selectivity and reactivity can be altered through changing the 
deoxygenation conditions. 
 
Therefore, attempts were made to vary the protecting group or silane to see if either 
of these parameters affected the amount of branching and elimination that occurred during 
the deoxgenation. In my first set of experiments, the identity of the protecting group was held 
constant at TMS (i.e. TMS-PVA) and the reducing silane was varied from diethylsilane to 
dimethylethylsilane to triethylsilane. In small molecule studies, when hydrosilanes were 
employed as the reducing agent, the reactions tended to proceed at a slower rate. However, in 
the case of all polymeric samples, no difference in reaction rate was observed when the 
hydrosilane was varied. The experiments were monitored by 13C-NMR spectroscopy to 
ensure complete deoxygenation was achieved.  For all three reaction conditions, the polymer 
was not fully deoxygenated until ~48 h reaction time was achieved. The samples were 
purified by treatment with pyridine-HF to remove excess silane and silyl ethers from the 
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deoxygenated materials. Following sample purification, 1H and 13C-NMR spectra were 
obtained on a Bruker Avance III 600 MHz spectrometer with CD2Cl2 or CDCl3 as the 
solvent. For all 13C-NMR analyses, a 0.05 M solution of Cr(acac)3, a relaxation agent, in the 
deuterated solvent was used to allow for quantitative analysis of the types of branches present 
in the structure. Each experiment was performed at least twice to obtain average branching 
and elimination values. 
By changing the reducing silane to the bulkier dimethylethylsilane (Table 2.2, Entry 
2), the calculated degree of branching decreased to about 150 branches per 1000 C, though 
the degree of elimination remained unchanged at ~12 alkenes per 1000 C. However, when 
triethylsilane was used (Table 2.2, Entry 3), the degree of branching was high (~260 
branches per 1000 C), and the number of alkenes remained at about 14 alkenes per 1000 C. 
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Table 2.2. 1H-NMR analysis of branching and elimination present in deoxygenated PVA 
polymer samples. 
Entry Polymera Silaneb # Branches 
(per 1000C)c 
# Alkenes 
(per 1000C)d 
1 TMS-PVA SiEt2H2 210 + 35 17 + 11 
2 TMS-PVA SiMe2EtH 150 + 5 12 + 8 
3 TMS-PVA SiEt3H 260 + 5 14 + 6 
4 SiMe2Et-PVA SiEt2H2 200 + 35 23 + 17 
5 SiMe2Et-PVA SiMe2EtH 165 + 35 24 + 4 
6 TES-PVA SiEt2H2 205 + 4 Trace 
7 TES-PVA SiMe2EtH 200* Trace 
a Prepared from 9-10,000 MW PVA. 
b Condtions for reductions: 5 mol% B(C6F5)3, xs. silane, in CH2Cl2, 35 °C, 48 hr.  
c By 1H-NMR spectroscopy of non-hydrogenated polymer using Equation 2.1. 
d By 1H-NMR spectroscopy of non-hydrogenated polymer using Equation 2.2. 
* Only 1 run was performed under these conditions. 
Additionally, the silyl protecting group was varied, and the branch and alkene 
numbers were calculated in the resulting deoxygenated polymers. As shown in Table 2.2, 
increasing the steric hindrance of the protecting group and silane did not lead to a clear trend 
in the branching or alkene number. Figure 2.7 shows the 1H-NMR spectra of the 
deoxygenated polymers resulting from reduction of TMS-PVA, SiMe2Et-PVA, and TES-
PVA. Each of the unique proton resonances were integrated and used in Equations 2.1 and 
2.2 to determine the degree of branching and elimination present in the polymer following 
complete reduction. Futher investigation into the polymer microstructures produced from the 
different hydrosilanes revealed very different branching structures. For instance, Figure 2.8 
compares the branching microstructure of the polymers derived from the deoxygenation of 
TMS-PVA, SiMe2Et-PVA, and TES-PVA.  
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Figure 2.8. 1H-NMR spectra of deoxygenated, non-hydrogenated TMS-PVA (top, in 
CDCl3), SiMe2Et-PVA (middle, in CDCl3), and TES-PVA (bottom, in CD2Cl2) used to 
calculate branch and alkene number (using SiEt2H2 as the hydrosilane). 
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Figure 2.9. 13C-NMR spectra of deoxygenated, hydrogenated TMS-PVA (top, in CDCl3), 
SiMe2Et-PVA (middle, CDCl3), and TES-PVA (bottom, in CD2Cl2). Deoxygenation of 
TMS-PVA results in a structure containing a high degree of methyl branches, whereas 
deoxygenation of TES-PVA results in a structure with ethyl yet no methyl branches. 
 
From the 13C-NMR spectra in Figure 2.8, one can reconstruct representative 
structures for the three different branched polymers (Figure 2.9). All three samples have 
branch numbers exceeding 200 branches per 1000 C, but the type of branches vary 
considerably. Deoxygenation of TMS-PVA results in a branched microstructure containing a 
large number of methyl branches, as indicated by the characteristic peaks at around 20 ppm 
in the 13C-NMR spectrum. As indicated by a peak at 11 ppm, this sample was devoid of ethyl 
branches. When SiMe2Et-PVA was reduced, the peak at ~20 ppm disappeared indicating a 
lack of methyl branches in the structure. Only long chain branches (C4+) were present in this 
sample. In the TES-PVA case, no methyl branches were present following deoxygenation. 
However, ethyl branches were present as seen in the 13C-NMR spectrum. The peak at 11 ppm 
44 
is characteristic of the methyl at the end of an ethyl branch. All three samples contained butyl 
or longer chains. 
 
Figure 2.10. Schematic representation of polymers obtained by deoxygenation of TMS- and 
TES-PVA as assessed by 13C-NMR analysis and comparing to the database of assignments 
compiled by Brookhart and McLain.11,13,14  
 
It should be noted that silyl exchange can occur between the protecting group and the 
hydrosilane in small molecule studies, the possibility of which complicates the analysis for 
these polymeric samples. For example, when starting with TMS-protected PVA and reducing 
with B(C6F5)3 and dimethylethylsilane, protecting group exchange could occur to provide a 
partially SiMe2Et-protected alcohol (Figure 2.10). Although one begins with a 
homogeneously protected polymer, the identity of the silyl-protecting group at the point of 
time that a specific C-O bond becomes reduced is ambiguous. In small molecule analogs, 
however, it has been observed that larger silicon-protecting groups tend to react slower.  
 
Figure 2.11. Proposed exchange of silicon-protecting group that can occur during the 
B(C6F5)3 reduction. 
 
Complete deoxygenation of silyl-protected PVA results in a highly branched 
polyolefin with branch numbers ranging from 150-210 branches per 1000 carbons. The 
presence of branches and alkenes in the deoxygenated polymer reveals that rearrangement 
Deoxygenation of TMS-PVA
•  No ethyl branches observed
•  Methyl branches present
Deoxygenation of TES-PVA
•  No methyl branches observed
•  Ethyl branches present
Deoxygenation of SiMe2Et-PVA
•  No methyl branches observed
•  No ethyl branches observed
OTMS OSiMe2Et
xs. SiMe2EtH
silyl exchange P 
P = TMS or SiMe2Et 
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and elimination occurs during the course of the reaction. However, attempts to study the 
mechanism in detail have proved difficult. The B(C6F5)3-catalyzed reduction of small 
molecule substrates produced the reduced alkane, along with minor eliminated products. The 
physical properties of polymers in solution (such as chain entanglement) make this system 
difficult to model.  Furthermore, silyl group exchange is likely occurring, compounding 
difficulties to determine the actual protecting group present at any given time during the 
reaction.  
2.3.3 Synthesis and Deoxygenation of a PBD-OH 
The methylene spacers between the hydroxyl groups were increased to study the 
deoxygenation of a 1,5-polyol (PBD-OH). A sample of polybutadiene was modified by a 
hydroboration-oxidation scheme to introduce the alcohol functionality. This is an alternative 
approach to copolymerizing ethylene and vinyl acetate (followed by hydrolysis), which 
would produce a similar polymer. However, polymerization of an olefin and vinyl acetate 
would lead to a random structure, and the alternating copolymerization of the two monomers 
in a precise 1:1 ratio is difficult to achieve. By hydroboration-oxidation of polybutadiene 
using a previously reported procedure,7 a regular alternating copolymer was synthesized 
(Scheme 2.3). First, polybutadiene was hydroborated with 9-BBN in THF. Subsequent H2O2 
oxidation yielded the desired polyol. The 13C-NMR spectrum confirmed that the hydroxyl-
functionality was present on every 4th carbon to form a 1,5-polyol (Figure 2.11). As shown in 
the 13C-NMR spectrum, minor signals were observed at ~35 ppm, perhaps resulting from 
regioirregularities (ie combinations of 1,3 and 1,5 diol arrays) or hydroxyl ethyl defects from 
hydroboration-oxidation of 1,2-insertion mistakes installed during the butadiene 
polymerization. Additionally, 13C-NMR analysis was used to determine the hydroxy-content; 
the isolated material was determined to be >98% hydroxylated. 
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Scheme 2.3. Hydroboration-oxidation of polybutadiene to form a 1,5-polyol. 
 
 
 
Figure 2.12. 13C-NMR spectrum of hydroxylated polybutadiene (in CDCl3), indicating a 
predominantly 1,5-polyol. If a 1,4- or 1,6- polyol formed, the spectrum would be more 
complex with 3 different peaks in the alkane region. 
 
Prior to deoxygenation, PBD-OH was silyl-protected with a range of protecting 
groups (TMS-, SiMe2Et-, or TES-) by reacting with the corresponding silyl chloride for 2-3 
days in the presence of pyridine. The silyl ethers were formed in good yields. The silyl 
protected-1,5-polyol was then deoxygenated using B(C6F5)3 and various hydrosilanes 
(Scheme 2.4). Following deoxygenation and deprotection using pyridine-HF, both 1H- and 
13C-NMR analysis was used to compare the branching and elimination in the polymer 
structure (Table 2.3). The protecting group used did not have an effect on the branch or 
alkene number as calculated from 1H-NMR spectra of non-hydrogenated polymers. In the 
case of the reducing silane, when the bulkier SiMe2EtH silane was used, initial trends suggest 
a decrease in branch number was achieved. For instance, deoxygenation of PBD-OTMS 
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using SiEt2H2 resulted in about 195 branches per 1000C and minimal alkenes (Table 2.3, 
Entry 1). Changing the silane to SiMe2EtH yielded a polyolefin with about 160 branches per 
1000C (Table 2.3, Entry 2). 
Scheme 2.4. General scheme for the deoxygenation of hydroxylated-polybutadiene. 
 
Table 2.3. 1H-NMR analysis of branching and elimination present in deoxygenated PBD-OH 
polymer samples. 
Entry Polymera Silaneb # Branches 
(per 1000C)c 
# Alkenes 
(per 1000C)d 
1 PBD-OTMS SiEt2H2 195 trace 
2 PBD-OTMS SiMe2EtH 160 trace 
3 PBD-OSiMe2Et SiEt2H2 195 trace 
4 PBD-OSiMe2Et SiMe2EtH 160 trace 
a Prepared from commercially available polybutadiene (MW=200-300,000). 
b Condtions for reductions: 5 mol% B(C6F5)3, xs. silane, in CH2Cl2, 35 °C, 48 hr.  
c By 1H-NMR spectroscopy of non-hydrogenated polymer using Equation 2.1. 
d By 1H-NMR spectroscopy of non-hydrogenated polymer using Equation 2.2. 
 
Again, the polyolefins were hydrogenated using Wilkinson’s catalyst to facilitate the 
NMR analysis of branching structure. Following hydrogenation, the 13C- NMR spectrum 
showed the disappearance of alkene peaks and a more simplified alkane region. The 
hydroxylated-polybutadiene system produced similar results to PVA deoxygenation. Both 
high molecular weight polymers were reduced to a highly branched polyolefin. Figure 2.12 
highlights the branched microstructure produced following deoxygenation of PBD-OTMS. 
The disappearance of the characteristic C-O peak at 72 ppm and the appearance of multiple 
peaks in the alkane region (10-45 ppm) were observed, indicating complete deoxygenation 
and skeletal rearrangement had occurred. Figure 2.14 highlights the difference in branching 
microstructure between deoxygenated PBD-OTMS and PVA-TMS. Comparison of the two 
OP exc. silane5 mol% B(C6F5)3
DCM, 48 h
40°C
branched polyolefin
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13C-NMR spectra suggests that a branched polyalkane was obtained, but the types of 
branches present following deoxygenation varies. 
 
Figure 2.13. Comparison of 13C-NMR spectra of PBD-OH (top) and deoxygenated PBD-
OTMS (with SiEt2H2) after pyridine-HF treatment. Following complete deoxygenation, a 
branched hydrocarbon structure is observed. 
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Figure 2.14. Comparison of 13C-NMR spectra of deoxygenated PBD-OTMS (top) and 
deoxygenated PVA-TMS (with SiEt2H2) after pyridine-HF treatment.  
 
Further experiments to decrease and possibly stop the branching are proposed. 
Investigations into acyclic diene metathesis (ADMET) polymerizations of alcohol-
functionalized dienes to form other linear polyols would provide another route to spread out 
the alcohol functionalities, which may hinder any neighboring group participation. 
Additionally, the concentration of the polymer in solution may have an impact on the branch 
number observed. For instance, using a lower polyol concentration in the deoxygenation may 
result in fewer alkyl shifts between chains due to less chain entanglement. 
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2.3.4 Investigation of Small Molecule Models 
The degree of branching for the deoxygenation of PVA-TMS with diethylsilane was 
determined to be approximately 170 branches per 1,000 carbons, which is equivalent to 
nearly one branch for every two monomer units. Therefore, it seems that the branching 
mechanism is occurring in a controlled manner. Small molecule model substrates were 
deoxygenated under the same reaction conditions to determine if similar rearrangement 
mechanisms were operative. First, 2-methyl-3-hexanol was selected as a model substrate 
because it would similarly contain an alcohol functionality next to a branch point. However, 
deoxygenation of 2-methyl-3-hexanol (Scheme 2.3) resulted in clean reduction of the alcohol 
to 2-methylhexane, i.e. no additional branching occured. Next, the small molecule diols, 2,5-
hexanediol and 2,4-pentanediol, were studied. After B(C6F5)3-reduction with diethylsilane, 
the major product in both cases was the reduced n-alkane with traces of alkene (Scheme 2.4 
and Scheme 2.5). Since screening of these small molecule substrate analogs failed to 
reproduce the branching behavior of the polymers, it suggests that the high MW polyols are 
inherently more complex. Key differences may include the entangled nature of polymers in 
solution, which may contribute to the alkyl shifting during the reaction mechanism. 
Scheme 2.5. Deoxygenation of 2-methyl-3-hexanol with B(C6F5)3 and diethylsilane. 
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Scheme 2.6. Deoxygenation of 2,5-hexanediol with B(C6F5)3 and diethylsilane. 
 
Scheme 2.7. Deoxygenation of 2,4-pentanediol with B(C6F5)3 and diethylsilane. 
 
2.3.5 Mechanistic Insights 
It is conceivable that the deoxygenation may proceed by a mechanism that exists on a 
continuum of pathways ranging from totally random deoxygenation or a blocky zipper-like 
process. If the deoxygenation occurs in a random manner, where any C-O site may be 
reduced, the intermediate structure will become more complex as the reaction initially 
proceeds (Figure 2.13). The starting PVA polymer is a simple, linear structure with two 
characteristic peaks at 67 and 47 ppm in the 13C-NMR spectrum. One might expect the 
structure to quickly increase in complexity if random C-O bonds are cleaved. If this were the 
case, the 13C-NMR spectrum of the partially deoxygenated material would show an 
immediate appearance of alkane branches in the 10-45 ppm region with the disappearance of 
the starting polymer peaks at 67 and 47 ppm. Additionally, the PVA peaks would become 
more complex, either through the appearance of additional peaks or an increase in broadness, 
with initial random deoxygenation.  
xs. SiEt2H2
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Figure 2.15. Possible deoxygenation mechanism in which the deoxygenation proceeds 
through a random process. In this case, one would expect the sample to go from a simple to 
highly complex to lower complexity structure, as observed in the 13C-NMR spectrum. P 
indicates silyl protecting group. 
 
Another pathway that the deoxygenation mechanism may proceed through is a 
“zipper” effect, in which deoxygenation begins at the least sterically hindered end of a polyol 
chain and reduces by walking down the chain reducing adjacent C-O bonds (Figure 2.14). In 
this scenario, the characteristic PVA peaks in the 13C-NMR spectrum should remain 
unchanged in complexity, but disappear as the deoxygenation proceeds. The alkane region 
would appear simpler with branches growing in as the reaction proceeded.  
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Figure 2.16. Possible deoxygenation mechanism in which the deoxygenation proceeds 
through a controlled, zippered process where deoxygenation starts at the least sterically 
hindered end and walks down the chain. P indicates the silyl protecting group. 
 
To probe the deoxygenation mechanism, an experiment that followed the 
deoxygenation over time was designed. Samples that tracked the deoxygenation of TMS-
PVA with B(C6F5)3/diethylsilane were obtained by quenching with triethylamine at specific 
time points (15 min, 1 h, 5 h, and 48 h). After quenching, in situ 13C-NMR spectra were 
obtained to capture the loss of PVA units and growth of polyalkane units and to determine if 
random C-O bonds were being reduced or if a zipper effect was occurring (Figure 2.15). 
Following treatment with B(C6F5)3 and diethylsilane for 15 minutes, the peak at 47 ppm from 
the methylenes of the starting PVA broadens and displays a new shoulder peak slightly 
upfield. This is accompanied by a significant number of peaks in the alkane region. Together, 
these observations therefore imply that the deoxygenation occurs in a mostly random 
manner. As random C-O bonds continue to be reduced, the structure grows in complexity (at 
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time points 1 h and 5 h), yet after complete deoxygenation, the branch points converge into a 
more simplified structure.   
 
Figure 2.17. Time course 13C-NMR analysis of the deoxygenation of TMS-PVA monitoring 
disappearance of starting material and appearance of branched product. Peak at 47 ppm, 
indicative of methylenes in starting polymer, initially broadens and then disappears at later 
times. Multiple peaks increase in intensity in alkane region (15-45 ppm), showing an increase 
in the number and types of branches as the reaction proceeds. 
 
 Attempts to study the deoxygenation reaction through timed NMR experiments 
proved difficult. The initial broadening of peak at 47 ppm from the starting methylenes in 
TMS-PVA, suggests that the structure becomes more complex. However, as time proceeds, 
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the peak sharpens, indicating a more simplified polymer structure. The complexity of the 
reaction and the structure complicates analysis of the deoxygenation reaction. 
2.4 Conclusions 
In conclusion, the hydrosilylative reduction of polyols using B(C6F5)3 and a 
hydrosilane to give a branched polymer has been demonstrated. Deoxygenation of linear 
polyols, such as PVA and PBD-OH, results in unsaturated branched polyolefins, where the 
branched microstructure is dependent on the silyl protecting group and the silane used as the 
hydride source. This makes it possible to develop polyolefins with unique branch structures. 
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 SYNTHESIS OF A LINEAR-BRANCHED-LINEAR TRIBLOCK Chapter 3.
POLYMER THROUGH HYDROSILYLATIVE DEOXYGENATION 
3.1 Introduction 
Block copolymers are a class of materials that have interesting properties due to the 
presence of different polymer blocks in the chain.59 Styrene-b-butadiene-b-styrene (SBS) and 
its hydrogenated version styrene-b-ethylene/butadiene-b-styrene (SEBS) are two widely used 
commercial triblock polymers.60,61 The combination of two incompatible materials allow for 
both elastic and thermoplastic behavior in the same material. By varying the length of the 
butadiene interior, different properties can be achieved.62 For instance, when a shorter 
butadiene block is present, the rigid material is used in plastic storage containers. Increasing 
the butadiene chain to a larger block size leads to a more rubbery material, which is ideal for 
use in applications like shoe soles. Hydrogenation of the butadiene interior block of SBS 
leads to a tougher material with greater weather resistance. 
                                                
59 Gould, R., Ed.; Multicomponent Polymer Systems. In Adv. Chem. Series, 1971, 99. 
 
60 Tschunker, E.; Bock, W. Rubberlike Mass Containing Styrene Polymerizates. U.S. Patent 
1,938,731, Dec 12, 1933. 
 
61 Ku, P. Adv. Polym. Tech. 1988, 8, 201-223. 
 
62 Holden, G. Thermoplastic Elastomers. In Encylopedia of Polymer Science and Technology 
[online]; Wiley & Sons, 2010. 
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In the previous chapter, an alternative method to synthesize branched polyolefins 
through deoxygenation of linear polyols was reported. The Lewis acid 
trispentafluorophenylborane B(C6F5)3 was used as a catalyst, along with silane, to reduce 
high MW polyols. Previous reports have used B(C6F5)3 as a mild catalyst in the reduction of 
primary and secondary alcohols.20,22,21,24 Typically, a hydrosilane, such as diethylsilane, is 
used as the hydride source in the reduction. Application of this chemistry to linear polyols 
resulted in highly branched polyolefins with branch numbers up to 236 (per 1000 C). The 
branching microstructure was dependent on the alcohol protecting group and silane used. 
In this chapter, the synthesis of a hydroxylated-SBS (SBS-OH), in which the 
polybutadiene block has every point of unsaturation converted to an alcohol by a 
hydroboration-oxidation sequence, is reported. Reduction of SBS-OH was achieved using 
catalytic amounts of B(C6F5)3 with hydrosilane. The material was completely deoxygenated 
to yield a new triblock polymer with a highly branched interior block. To the best of our 
knowledge, the synthesis of a linear-highly branched-linear triblock polymer has not yet been 
reported. 
3.2 Experimental 
3.2.1 Materials 
The deoxygenation reactions were performed inside a Vacuum Atmospheres 
glovebox under an argon atmosphere. All chemicals were purchased from Sigma Aldrich or 
Fischer Scientific unless otherwise noted. Tris(pentafluorophenyl)borane was purchased 
from Gelest, Inc. Methylene chloride was degassed via three freeze-pump-thaw cycles and 
dried over 4Å molecular sieves prior to use. Diethylsilane was dried over 4Å molecular 
sieves prior to use.  
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3.2.2 Instrumentation and Analysis 
NMR spectra were recorded using a Bruker Avance III spectrometer equipped with a 
cryoprobe operating at 600 MHz (1H) or 150 MHz (13C). NMR chemical shifts are reported 
in ppm and internally referenced using the residual proton peaks (1H) or the 13C resonances 
of the deuterated solvent (13C). All NMR spectra were recorded in CDCl3 or CD2Cl2 unless 
otherwise noted. For 13C-NMR spectroscopy, chromium(III) acetate (Cr(acac)3) was added as 
a relaxation agent to all polymer samples prior to collecting spectra (d1 = 1 s). 
3.2.3 Synthesis of Poly(styrene-b-butanol-b-styrene) 
 
SBS triblock polymers were hydroborated and oxidized using a similar procedure as 
previously reported.51 A typical hydroboration-oxidation was done as following: 0.5 g of 
polymer was combined with 50 mL of 0.5 M 9-BBN in THF under an N2 atmosphere. The 
reaction was stirred for 3 days at room temperature. To the resulting solution, a mixture of 
NaOH (3.0 M, 2.0 mL) and aqueous H2O2 (30%, 2.0 mL) was added at 0 °C. The reaction 
mixture was allowed to stir at room temperature overnight. A white precipitate formed. The 
mixture, including the precipitate, was dialyzed against 1:1 MeOH: water for 5 hours, or until 
the pH was neutral. The MeOH: water was changed hourly. The reaction mixture was then 
removed from the dialysis tubing, the insoluble fraction was dried under vacuum, and the 
soluble fraction was rotovapped to isolate the soluble polyol fraction (SBS-OH). 
 
 
1) 9-BBN, THF
2) H2O2, NaOH
OH
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3.2.4 General Deoxygenation Procedure 
In a nitrogen-filled glovebox, SBS-OH (50 mg) and B(C6F5)3 (5 mol% relative to 
monomer) was combined with 0.250 mL CD2Cl2 or CH2Cl2. Then, 0.250 mL of silane 
(diethylsilane, dimethylethlsilane, or triethylsilane) was added. The solution was immediately 
capped with a vented cap and swirled. After gas evolution subsided, the reaction mixture was 
transferred to a septum-capped NMR tube and removed from the glovebox to continue 
reacting for 48 h at 35 °C. At this point, NMR spectra were obtained if desired. 
3.2.5 General Silane Removal Procedure 
To remove excess silane and silyl ether from the deoxygenation reaction, the reaction 
mixture was added to a 15-mL plastic centrifuge tube. To the centrifuge tube, 0.80 mL of 
pyridine-HF was added. The reaction mixture was treated with pyridine-HF for 24 h. Silica 
was then added to remove any excess HF present. The silica was isolated by vacuum 
filtration, and the filtrate was rotovapped to yield the deoxygenated triblock polymer. 
3.2.6 General Hydrogenation Procedure 
The branched polyolefin was dissolved in 2.0 mL of CH2Cl2 and transferred to a 
Fisher-Porter vessel. Wilkinson’s catalyst (1 mol%) was added, and the vessel was put under 
40 psi of H2. The reaction was allowed to stir at 40 °C for two days. The catalyst was 
removed by vacuum filtering over a silica plug, which was washed with 10 mL of CH2Cl2. 
The solvent was then removed by rotary evaporation to yield the hydrogenated, branched 
polymer. 
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3.2.7 Hydrogenation of SBS 
The SBS polymer was hydrogenated based on a previously reported procedure.63 In a 
Schlenk flask, SBS (0.5 g) was dissolved in 25 mL of p-xylene, and 0.025 mL of BHT was 
added. Tosylhydrazide (1.9 g) was added to the flask, and the mixture was degassed twice by 
freeze-pump-thaw cycles. The solution was placed under a N2 atmosphere, and a reflux 
condenser was attached to the Schlenk flask. The mixture was heated at 120 °C for 3 days. 
The solution was cooled to room temperature before pouring into rapidly stirring methanol to 
isolate the hydrogenated SEBS. The polymer was dried under vacuum (65% yield, 85% 
hydrogenated by NMR analysis).  
3.3 Results and Discussion 
3.3.1 Synthesis and Deoxygenation of Hydroxylated-SBS 
The molecular weight of styrene-b-butadiene-b-styrene was to be 50,900 from by 
GPC. The triblock polymer contains 30 wt% styrene, which is equivalent to approximately 
roughly 140 PS and 650 butadiene repeat units. The interior butadiene block was post-
synthetically modified to incorporate alcohol functionalities. SBS was hydroborated and 
oxidized using a previously reported procedure (Scheme 3.1). First, SBS was treated with 9-
BBN to hydroborate the polymer. Subsequent H2O2 oxidation led to formation of a white 
precipitate. The reaction mixture, including the precipitate, was dialyzed to remove any salts. 
The precipitate was then isolated by vacuum filtration. Attempts were made to dissolve the 
precipitated solid with no success. Therefore, it is suspected that a material with ether 
crosslinks formed.  
                                                
63 Wu, Z.; Grubbs, R. H. Macromolecules 1995, 28, 3502-3508. 
61 
Scheme 3.1. Hydroboration-Oxidation of SBS. 
 
The crosslinked SBS-OH precipitate was deoxygenated using catalytic amounts of 
B(C6F5)3 with diethylsilane with a procedure that simultaneously protects the free alcohols as 
the silyl ethers. The reaction mixture was heated at 35 °C for 3 days to achieve complete 
deoxygenation. As the reaction proceeded and the proposed ether linkages were cleaved, the 
material was solubilized. 13C-NMR analysis was used to monitor the reaction progress 
through disappearance of the C-O bonds at ~70 ppm in the spectrum. As the material began 
to solubilize, a peak at ~70 ppm appeared in the spectrum indicative of remaining C-O 
bonds. However, following complete deoxygenation, this peak disappeared completely. To 
remove excess silane and silyl ethers from the deoxygenated polymer, the sample was treated 
with pyridine-HF, which breaks up the Si-O bonds through formation of the stronger Si-F 
bond.52 Excess silica gel was added to quench any remainder HF. The deoxygenated polymer 
was isolated by filtration, and the solvent was removed to isolate an oily substance.  
Scheme 3.2. B(C6F5)3-catalyzed deoxygenation of SBS-OH. 
 
Both 1H- and 13C-NMR analysis were used to study the deoxygenated polymer 
structure. The 13C-NMR spectrum confirms that deoxygenation was in fact achieved and that 
skeletal rearrangement occurred during the reaction to produce a linear-branched-linear 
triblock system. In the case of a homopolymer, 1H-NMR spectroscopy is typically used to 
1) 9-BBN, THF
2) H2O2, NaOH
OH
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determine the branch number through comparative integration of the methyl protons of the 
branches relative to the total proton integration.14 However, the degree of branching could 
not be determined through similar analysis, as the protons of the styrene block tend to 
overlap with the methyl and methine protons of the branched polyolefin interior. 
 
Figure 3.1. 1H-NMR analysis of (left) highly branched polyolefin synthesized through 
B(C6F5)3/diethylsilane deoxygenation of PVA-TMS and of branched triblock polymer (right). 
The degree of branching cannot be determined through integration due to overlap of the PS 
protons. 
 
Further analysis of the 13C-NMR spectrum was conducted to determine the types of 
branching present in the triblock polymer. In terms of the butadiene block, the resulting 
alkene can be formed in three different ways: cis, trans, and vinyl.64 The cis and trans 
isomers arise from 1,4 polymerization, whereas the vinyl form results from 1,2-
                                                
64 Obrecht, W.; Lambert, J.; Happ, M.; Oppenheimer-Stix, C.; Dunn, J.; Kruger, R. Rubber, 4. 
Emulsion Rubbers. In Ullmann’s Encyclopedia of Industrial Chemistry; 2001. 
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polymerization of butadiene. The properties of the three different forms vary. Cis-
polybutadiene has a high elasticity, whereas the trans-polybutadiene is rather straight, 
forming microcrystalline regions in the chain. The vinyl groups can appear as branch points 
in the deoxygenated structure. Therefore, it was necessary to hydrogenate SBS to provide a 
reference structure for comparison. SBS was hydrogenated through use of tosylhydrazide via 
in situ generation of a diimide to form SEBS (Scheme 3.3).   
Scheme 3.3. Hydrogenation of SBS with tosylhydrazide in xylene to form SEBS. 
 
As shown in Figure 3.1, the 1H-NMR spectrum of SEBS confirmed that the material 
was 85% hydrogenated. The allylic protons in the starting material appear at 1.96 ppm, and 
the methylene protons in the hydrogenated product appear at 1.25 ppm. The relative 
integrations of these peaks were used to determine the hydrogenation percentage. The 13C-
NMR spectrum of SEBS (Figure 3.3) does show the presence of alkenes in the 120-140 ppm 
region, indicating that full hydrogenation was not achieved.  
tosylhydrazide
BHT
p-xylene
120°C, 3 h
64 
 
Figure 3.2. 1H-NMR spectrum of hydrogenated SBS (SEBS) in CDCl3. Only 85% 
hydrogenation of the sample was achieved, as indicated by the residual alkene peak at 5.4 
ppm. 
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Figure 3.3. 13C-NMR spectrum (CDCl3, 0.5 M Cr(acac)3)  of SBS that is ~85% 
hydrogenated as calculated from 1H-NMR spectroscopy (Figure 3.2). The PS aromatic peaks 
are found at 145, 130, 128, and 125 ppm, while the PS backbone makeup the broad peak at 
40 ppm. The peak at 29 ppm is characteristic of the methylene backbone of the hydrogenated 
interior block. The remaining peaks are indicative of defects from the polymerization. 
 
The defects present in the butadiene interior block of SEBS were further analyzed by 
13C-NMR spectroscopy. Figure 3.4 shows the alkane region of the NMR spectrum and 
provides further peak assignments based on the known defects present. The 15% of 
unhydrogenated polybutadiene exists as 1,4-cis, 1,4-trans, or vinyl groups. Because complete 
hydrogenation was not achieved, all three of these forms are observed in the 13C-NMR 
spectrum. For instance, the allylic carbon from 1,4-cis polymerization appears at 32.32 ppm, 
and the allylic carbon from 1,4-trans polymerization is observed at 26.91 ppm. The carbon at 
a vinyl branch appears at 38.53 ppm. After hydrogenation, the vinyl group becomes an ethyl 
branch off the polymer backbone, with peaks observed at 25.57 and 10.58 ppm. 
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Figure 3.4. 13C-NMR spectrum (CDCl3, 0.5 M Cr(acac)3) of alkane region of hydrogenated 
SBS (SEBS) with assigned chemical shifts to highlight defects in the butadiene block. 
 
 The hydrogenated SEBS material was then compared to the deoxygenated triblock 
sample. Figure 3.5 overlays the 13C-NMR spectra of SEBS and the deoxygenated product. 
Not only are the expected defects from the butadiene polymerization observed in the NMR 
spectrum of the deoxygenated material, but additional peaks due to branching are observed. 
The branches were assigned based on previous assignments in the literature.55,56,57The 
branching observed is predominantly long chains. For instance, the peak at 14 ppm is 
indicative of methyls from butyl and larger chains, while the peak at 22.5 ppm indicates the 
2nd carbon from the end of the chain for pentyl and larger branches. It should be noted that 
the broad peak from 40-41 ppm due to the polystyrene block is unchanged after the 
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hydrosilylative reduction, which suggests that the polystyrene unit is not rearranging during 
the reaction. 
 
Figure 3.5. 13C-NMR analysis of SEBS (top) and deoxygenated SBS-OH (bottom). 
Following B(C6F5)3-catalyzed deoxygenation, a linear-branched-linear structure is formed. 
3.4 Conclusions 
In conclusion, the hydrosilylative reduction of SBS-OH using B(C6F5)3 and a 
hydrosilane to yield a linear-branch-linear triblock polymer has been demonstrated. As 
discussed in the previous chapter, deoxygenation of linear polyols, such as PVA and PBD-
OH, results in unsaturated branched polyolefins. This chemistry was applied to a triblock 
system as a way to synthesize an otherwise inaccessible linear-branched-linear material. 
Following B(C6F5)3-catalyzed deoxygenation, the triblock branching architecture was 
analyzed by 13C-NMR. The predominant branches observed were of butyl and larger lengths. 
The glass transition temperatures and phase-separation properties are currently being 
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investigated. By varying the length of the polybutadiene block, materials with different 
properties may be obtained.  
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 PLATINUM BISPHOSPHONATE COMPLEXES AS THERANOSTIC Chapter 4.
AGENTS 
4.1 Introduction 
Cisplatin has been used in the clinic since 1978 to treat a variety of cancers, including 
testicular, lung, breast, and ovarian.65  The widespread success of cisplatin has resulted in the 
synthesis and study of many other platinum anticancer drugs, yet only two other platinum 
complexes, oxaliplatin and carboplatin, have been approved by the FDA.66,67 All three of 
these platinum complexes inhibit cancer cell growth by binding to DNA causing structural 
distortions that trigger programmed cell death.65,68 Although platinum anticancer drugs are 
still widely used in the clinic, the performances of the drugs are limited by their poor 
pharmacokinetic properties. The severe side effects, including nephrotoxicity and 
neurotoxicity, associated with platinum drugs reduce a patient’s quality of life.69 
Furthermore, inherent or acquired tumor resistance limits the effectiveness of cisplatin.70 
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Therefore, strategies to effectively deliver active platinum drugs to the tumor were explored.  
Ideally, an effective delivery system for anticancer drugs, such as cisplatin, would 
deliver and release the drug selectively to the tumor. Recent discoveries in the area of cancer 
nanotherapeutics provide promise for selective drug delivery to the tumor site. Nanoparticles, 
in the size range of 10 to 200 nm, have emerged as a class of cancer chemotherapeutics. 
Nanoparticle-based therapeutic agents have several advantages over traditional small-
molecule agents, including high agent loading, tunable size, tailorable surface properties, 
controllable drug release kinetics, and improved pharmacokinetics.33,45,71,72,73,74,75 
Nanoparticles also tend to have increased accumulation in tumors as a result of the enhanced 
permeability and retention (EPR) effect that results from the leaky tumor neovasculatures and 
poor functioning lymphatic system. Additionally, nanoparticles can be specifically targeted 
to cancer cells by surface conjugation of an appropriate ligand to further enhance the 
accumulation of nanoparticles in tumors. The clinical success of nanoparticle-based 
therapeutics such as Doxil illustrates the potential of nanomaterials in anticancer drug 
delivery. The Lin group has previously developed nanoscale coordination polymers (NCPs) 
as a potential delivery vehicle for cisplatin prodrugs. 46,47 These materials demonstrated high 
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agent loading and comparable cytotoxicity to cisplatin in vitro. However, these materials 
readily degrade under physiological conditions, thus limiting their in vivo efficacy. 
Therefore, alternative nanoparticle platforms that possess minimal drug release and 
nanoparticle decomposition when circulating in the bloodstream, but also readily release the 
drugs in the reducing tumor microenvironment or upon cellular internalization, were 
developed. 
This chapter reports the development of cisplatin-based NCPs that exhibit controlled 
drug release. A platinum(IV) prodrug was synthesized, and then covalently incorporated into 
the nanoparticle through a reverse microemulsion method in which the platinum precursor 
binds to a metal center. Two different metal systems were studied: a calcium-based cisplatin 
nanoparticle and a manganese-based cisplatin nanoparticle. Calcium was selected due to its 
biocompatibility,48 and manganese was studied due to its applicability as a MRI contrast 
agent. The cisplatin-containing NCPs were then lipid coated to increase stability and blood 
circulation time (Scheme 4.1). Finally, the nanoparticles were in vitro evaluated against 
human non-small cell lung cancer cell lines. 
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Scheme 4.1. Synthesis and lipid coating of PtBP nanoparticles containing either Ca2+ or 
Mn2+. 
 
4.2 Materials and Methods 
4.2.1 General Materials and Methods 
 All starting materials were purchased from either Fisher Scientific or Sigma-Aldrich 
and used without further purification unless otherwise noted. Cisplatin was purchased from 
AK Scientific. DOPC (DOPC= 1,2-dioleoyl-sn-glycero-3-phosphocholine) and DSPE-PEG2K 
(DSPE-PEG2K= 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
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glycol)-2000]) were purchased from Avanti Polar Lipids. Fetal bovine serum (FBS, Sigma), 
RPMI-1640 growth medium (Gibco), penicillin-streptomycin (Sigma), trypsin-EDTA 
(Sigma), and phosphate buffered saline (PBS, Gibco) were purchased from the Tissue 
Culture Facility in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill. 1H-
NMR spectra were obtained on a 400 MHz Bruker DRX spectrometer. Thermogravimetric 
analyses (TGA) were performed on a Shimadzu TGA-50 equipped with a platinum pan at a 
sampling rate of 3 °C/min. A JEM 100CX-2 transmission electron microscope (TEM) was 
used to determine particle size and morphology. Dynamic light scattering (DLS) 
measurements were collected with a Malvern Zetasizer Nano Zs. Inductively-coupled plasma 
mass spectrometry (ICP-MS) was performed on a Varian 820-MS Inductively-Coupled 
Plasma Mass Spectrometry.  
A549 human non-small cell lung carcinoma cells (ATCC# CCL-185) and NCI-H460 
human non-small cell lung carcinoma cells (ATCC# HTB-177) were purchased from the 
Tissue Culture Facility of the Lineberger Comprehensive Cancer Center at the University of 
North Carolina at Chapel Hill. A549 cells were cultured in RPMI-1640 growth medium 
(Cellgro) supplemented with 10% fetal bovine serum (Sigma) and 2% pencillin-streptomycin 
(Sigma). H460 cells were cultured in RPMI-1640 growth medium (Cellgro) supplemented 
with 10%FBS (Mediatech) and 2% penicillin-streptomycin solution (Sigma).  
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4.2.2 Synthesis of Platinum Complexes 
4.2.2.1 Synthesis of c,c,t-Pt(NH3)2Cl2(OH)2 
 A reported procedure was modified in order to synthesize c,c,t-Pt(NH3)Cl2(OH)2.76  
Cisplatin (5.0298 g, 0.017 mol), water (100 mL), and 30% hydrogen peroxide (100 mL) were 
combined in a 500-mL round bottom flask. The reaction mixture was stirred in the dark at 50 
°C for 2 hours. It was then cooled to room temperature and placed in the refrigerator 
overnight to encourage precipitation of the product out of solution. The bright yellow product 
was collected by vacuum filtration and washed with water, acetone, and ether (75% yield). 
Synthesis of c,c,t,-Pt(NH3)2(phosphonocarbamate ester)2: A reported procedure was 
modified in order to synthesize c,c,t,-Pt(NH3)2(phosphonocarbamate ester)2.77 In a 20-dram 
vial, c,c,t-Pt(NH3)Cl2(OH)2 (884.5 mg, 2.65 mmol) was combined with DMF (3 mL). In a 
separate vial, diethoxyphosphinyl isocyanate (1.630 mL, 10.6 mmol) was combined with 
DMF (2 mL). The isocyanate mixture was added dropwise, with stirring, to the platinum 
mixture. The reaction mixture was stirred overnight at room temperature in the dark. The 
resulting solution was then filtered. Diethyl ether was added to the filtrate to precipitate out 
the desired product. The yellow product was isolated via centrifugation and washed twice 
with diethyl ether (80% yield).  
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4.2.2.2 Synthesis of c,c,t,-Pt(NH3)2(phosphonocarbamate)2 (PtBP) 
Under an inert atmosphere, dry c,c,t,-Pt(NH3)2(phosphonocarbamate ester)2 (1.465 g, 
2.17 mmol) was dissolved in anhydrous DMF (3.0 mL). Then, TMS-Br (2.81 mL, 21.2 
mmol, 10 equiv.) was added dropwise at 0°C. The reaction mixture was stirred overnight at 
room temperature in the dark under a N2 atmosphere. The product was crashed out overnight 
in the fridge after the addition of DCM. The product was isolated via centrifugation and 
washed twice with DCM. It was then dissolved in methanol (10 mL) and stirred overnight at 
room temperature in the dark. The light yellow product was crashed out with DCM, isolated 
via centrifugation, and washed twice with DCM (60% yield).  
4.2.3 Nanoparticle Synthesis 
4.2.3.1 Synthesis of Mn-PtBP and Ca-PtBP Nanoparticles 
In a 20-dram vial, 3 M NaOH (183 µL, 0.55 mmol) and 3.017 mL of milliQ water 
were combined. Then, PtBP (80 mg, 0.15 mmol) was dissolved into the solution via 
sonification. In a 100-mL flask, 25 mL of 0.3 M tritonX-100/1.5 M 1-hexanol in cyclohexane 
was combined with 1.0 mL of an aqueous metal salt solution (either MnCl2 or CaCl2, 100 
mg/mL). This solution was stirred rapidly for 10 minutes. In a separate 50-mL RB flask, 25 
mL of tritonX-100/1.5 M 1-hexanol in cyclohexane was combined with 1.0 mL of the PtBP 
solution and 100 µL of DOPA (200 mg/mL in CHCl3). This solution was stirred rapidly for 
10 minutes before adding to the metal salt solution. Once the two solutions were combined, 
the microemulsion was stirred rapidly for 30 min in the dark at room temperature. Ethanol 
was added to the reaction mixture to induce precipitation of the nanoparticles overnight. The 
following day, the particles were isolated via centrifugation (13,000 rpm x 15 min). The 
particles were then redispersed into 15 mL of cyclohexane and crashed out with 10 mL of 
ethanol. The particles were isolated by centrifugation (13,000 rpm x 20 min). The particles 
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were then redispersed into 15 mL of THF and crashed out with 10 mL of ethanol. The 
particles were isolated by centrifugation (13,000 rpm x 15 min), and redispersed into 10 mL 
of THF for storage. The particles were allowed to settle overnight to remove any large 
aggregates. They were then filtered through a 0.45 um PFTE filter, followed by a 0.2 um 
filter. 
4.2.3.2 Synthesis of Ca-Control and Mn-Control Nanoparticles 
In a 100-mL flask, 0.3 M triton-100/1.5 M 1-hexanol (25.0 mL) was combined with 
1.0 mL of an aqueous metal salt solution (either MnCl2 or CaCl2, 100 mg/mL in water), and 
stirred rapidly for 10 min. In a separate 50-mL flask, 0.3 M triton-100/1.5 M 1-hexanol (25.0 
mL) was combined with sodium pyrophosphate (1.0 mL, 25 mg/mL in water) and DOPA 
(200 µL, 200 mg/mL in CHCl3), and stirred rapidly for 10 min. The pyrophosphate solution 
was rapidly poured into the metal solution. The reaction mixture was stirred rapidly for 30 
min in the dark at room temperature. Ethanol was added in order to precipitate out the 
particles. The following day, the nanoparticles were isolated by centrifugation, and washed 
with cyclohexane/ethanol followed by THF/ethanol. The nanoparticles were stored in THF. 
4.2.4 Lipid Coating of Nanoparticles 
4.2.4.1 Lipid Coating of Ca-PtBP, Mn-PtBP, Ca-Control, and Mn-Control 
 DOPC (5 mg/mL in THF), cholesterol (5 mg/mL in THF), and DSPE-PEG2K (5 
mg/mL in THF) were removed from the freezer and heated to 50 °C using a water bath. To a 
1-dram vial was added 84 µL of DOPC, 42 µL of cholesterol, and 150 µL of DSPE-PEG. The 
volume of THF was evaporated to ~100 µL using a stream of nitrogen. Then, 0.5 mg of 
nanoparticles (stored in THF) was added, and the volume was evaporated back down to ~100 
µL. Another 1-dram vial containing a stir bar was placed in the 50 °C water bath, and 0.5 mL 
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of 30% ethanol in water was added to it. The nanoparticle solution was slowly added 
dropwise with stirring to the 30% ethanol. Blowing a stream of nitrogen in the vial 
evaporated the THF off completely. The sample was incubated at 50 °C without stirring for 5 
min. The sample was then cooled to room temperature. The free liposomes were removed by 
centrifuging at 13,000 rpm for 10 min. The lipid-coated particles were redispersed into PBS. 
4.2.4.2 Anisamide Targeting of Ca-PtBP and Mn-PtBP 
DOPC (5 mg/mL in THF), cholesterol (5 mg/mL in THF), DSPE-PEG2K (5 mg/mL in 
THF), and DSPE-PEG2K-AA (1 mg/mL in THF) were removed from the freezer and heated 
to 50 °C using a water bath. To a 1-dram vial was added 84 µL of DOPC, 42 µL of 
cholesterol, 150 µL of DSPE-PEG, and 30 µL of DSPE-PEG-AA. The volume of THF was 
evaporated to ~100 µL using a stream of nitrogen. Then, 0.5 mg of nanoparticles (stored in 
THF) was added, and the volume was evaporated back down to ~100 µL. Another 1-dram 
vial containing a stir bar was placed in the 50 °C water bath, and 0.5 mL of 30% ethanol in 
water was added to it. The nanoparticle solution was slowly added dropwise with stirring to 
the 30% ethanol. Blowing a stream of nitrogen in the vial evaporated the THF off 
completely. The sample was incubated at 50 °C without stirring for 5 min. The sample was 
then cooled to room temperature. The free liposomes were removed by centrifuging at 
13,000 rpm for 10 min. The lipid-coated particles were redispersed into PBS. 
4.2.5 Stability Assays 
4.2.5.1 BSA Stability Assay of Ca-PtBP@Lipid and Mn-PtBP@Lipid 
 The lipid-coated particles were combined with 5 mg of BSA. The sample was 
sonicated briefly to dissolve the BSA. Size measurements were obtained on the DLS every 
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10 minutes for 12 hours to detect whether the albumin protein adsorbed onto the surface of 
the nanoparticle. 
4.2.5.2 Platinum Release from PtBP Nanoparticles 
5 mg of PtBP nanoparticles were prepared in 500 µL PBS and placed in dialysis 
tubing (MW cutoff = 10,000). The dialysis tubing was submerged in a beaker containing 400 
mL 5 mM PBS at 37 °C. This concentration of PBS was chosen because it exceeds the 
concentration of phosphate in the blood. At selected time intervals, 1 mL of sample was 
removed from the beaker. The samples were digested in concentrated HNO3 for several hours 
before diluting with H2O.  The diluted samples were then analyzed by ICP-MS for platinum 
content (in ppb). The platinum content was used to calculate the percent drug release from 
the nanoparticles. 
4.2.6  In Vitro Cell Viability Assays 
4.2.6.1 A549 Cell Viability Assay using PtBP@Lipid Nanoparticles 
Confluent A549 cells were trypsinized and counted with a hematocytometer. Cells 
were plated in 96-well plates at a cell density of 1,000 cells/well and 100 µL of medium. 
Plates were incubated at 37°C, 5% CO2, overnight. Media was removed from wells, and 
each well was washed with PBS. Drug/particle solutions were prepared in media containing 
5% PBS. Aliquots of drug/particle solutions and media (5% PBS) were given to each well to 
result in cisplatin concentrations of 0, 0.75, 1.5, 3.75, 7.5 and 15 µM. Plates were incubated 
for 3 days, and viability was determined via the MTS assay. 
4.2.6.2 H460 Cell Viability Assay using PtBP@Lipid Nanoparticles 
 Confluent H460 cells were trypsinized and counted with a hematocytometer. Cells 
were plated in 96-well plates at a cell density of 1,000 cells/well and 100 µL of medium. 
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Plates were incubated at 37°C, 5% CO2, overnight. Media was removed from wells, and 
each well was washed with PBS. Drug/particle solutions were prepared in media containing 
5% PBS. Aliquots of drug/particle solutions and media (5% PBS) were given to each well to 
result in cisplatin concentrations of 0, 0.75, 1.5, 3.75, 7.5 and 15 µM. Plates were incubated 
for 3 days, and viability was determined via the MTS assay. 
4.2.6.3 H460 Cell Viability Assay using MnPtBP@LipidAA Nanoparticles 
Confluent H460 cells were trypsinized and counted with a hematocytometer. Cells 
were plated in 96-well plates at a cell density of 1,000 cells/well and 100 µL of medium. 
Plates were incubated at 37°C, 5% CO2, overnight. Media was removed from wells, and 
each well was washed with PBS. Drug/particle solutions were prepared in media containing 
5% PBS. Aliquots of drug/particle solutions and media (5% PBS) were given to each well to 
result in a range of cisplatin concentrations. Plates were incubated for 3 days, and viability 
was determined via the MTS assay. 
4.3 Results and Discussion 
4.3.1 Synthesis of Platinum Complexes 
The platinum(IV) complex c,c,t,-Pt(NH3)2(phosphonocarbamate)2 (PtBP) was 
synthesized starting from commercially available cisplatin (Scheme 4.2).  First, cisplatin was 
oxidized using hydrogen peroxide to form the dihydroxy-platinum complex c,c,t-
Pt(NH3)2Cl2(OH)2 in up to 80% yields. Diethoxyphosphinyl isocyanate was treated with the 
dihydroxy-platinum complex to form a carbamate with an 82% yield. The hydroxyl groups 
are known to act as a nucleophile and rapidly attack the electrophilic carbon atom of the 
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isocyanate group.78 The platinum-based ester was then hydrolyzed to form the desired PtBP 
in a 60% yield. The platinum complex has two orthogonal phosphonate groups to allow for 
coordination to a metal ion, in this case either Mn2+ or Ca2+. 
Scheme 4.2. Synthesis of c,c,t,-Pt(NH3)2(phosphonocarbamate)2 (PtBP): a) oxidation of 
cisplatin with hydrogen peroxide, b) formation of platinum-carbamate species through 
nucleophilic substitution, and c) hydrolysis of platinum-ester to form PtBP. 
 
4.3.2 Synthesis of Control, Ca-PtBP, and Mn-PtBP Nanoparticles 
 A reverse, or water-in-oil, microemulsion was used to synthesize nanoparticles 
containing a metal ion (either Mn2+ or Ca2+) and PtBP. Ca-PtBP and Mn-PtBP corresponds 
to the resulting nanoparticles synthesized using either Ca2+ or Mn2+, respectively. To 
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synthesize the metal-PtBP nanoparticle, a reverse microemulsion of 0.3 M Triton X-100 and 
1.5 M 1-hexanol in cyclohexane with a water to surfactant ratio (W value) of 7.4 was used. 
The PtBP complex was dissolved into an aqueous basic solution to deprotonate the 
phosphonic acids, and the solution was added rapidly to the oil phase with stirring, followed 
by addition of an aqueous metal ion solution. A small amount of DOTAP (DOTAP= 1,2-
dioleoyl-3-trimethylammonium-propane) was added to the reverse microemulsion in order to 
aid in nanoparticle stabilization. The DOTAP remains at the oil-water interface, with its 
hydrophobic tails in the oil phase and its polar head groups in the water phase. In the water 
phase, the phosphonate groups of either the PtBP complex or DOTAP coordinate to the metal 
ions, polymerizing to form a NCP (Scheme 4.3). Due to the hydrophobicity of the DOTAP 
chains, it is expected that the DOTAP will be on the surface rather than in the interior of the 
nanoparticle. The polymerization reaction was quenched by the addition of ethanol, and the 
particles were isolated by centrifugation. Washing with ethanol aids in removal of excess 
surfactant from the nanoparticles. 
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Scheme 4.3. Synthesis of metal-PtBP (Ca-PtBP or Mn-PtBP) nanoparticles through a 
reverse microemulsion. 
 
To characterize the Ca-PtBP and Mn-PtBP nanoparticles, images were obtained 
using TEM (Figure 4.1). Nanoparticle Ca-PtBP was spherical and approximately 15 nm in 
diameter, while nanoparticle Mn-PtBP was approximately 20-25 nm in diameter. Dynamic 
light scattering (DLS) measurements of Ca-PtBP and Mn-PtBP in THF had unimodal 
distributions that corresponded roughly to the TEM diameters (Figure 4.2, Table 4.1). 
Inductively coupled plasma-mass spectroscopy (ICP-MS) confirmed a cisplatin loading of 
20% for Ca-PtBP and 25% for Mn-PtBP. 
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Figure 4.1. TEM images of Ca-PtBP (a) and Mn-PtBP (b). Scale bars equal 200 nm. 
 
Figure 4.2. Number weighted DLS spectrum of Ca-PtBP (black) and Mn-PtBP (red). 
 
Table 4.1. DLS measurements for Ca-PtBP and Mn-PtBP obtained in THF. 
Nanoparticle Z Average (nm) PDI Number Average (nm) 
Ca-PtBP 88.50 0.276 30.22 
Mn-PtBP 66.6 0.183 33.86 
Ca-control 45.35 0.285 25.69 
Mn-control 33.79 0.199 18.75 
 
Using a similar procedure, cisplatin-free nanoparticles (Ca-control and Mn-control) 
were synthesized as a control. Instead of using PtBP as the linker, pyrophosphate was used 
(Scheme 4.4).  The DLS measurements are reported in Table 4.1. These particles were 
a) b) 
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synthesized to ensure that no cell cytotoxicity occurs from the metal ions or phosphonate 
groups present in the nanoparticles. 
Scheme 4.4. Synthesis of Ca-control and Mn-control nanoparticles. 
 
4.3.3 Lipid Coating of Control, Ca-PtBP, and Mn-PtBP 
To impart stability and biocompatibility, nanoparticles Ca-control, Mn-control, Ca-
PtBP, and Mn-PtBP were coated with PEGylated liposomes (Scheme 4.5) to form Ca-
control@Lipid, Mn-control@Lipid, Ca-PtBP@Lipid, and Mn-PtBP@Lipid, 
respectively. Liposomes act as a delivery vehicle for the nanoparticles, with the presence of 
PEG increasing blood circulation time by shielding the particles from the mononuclear 
phagocyte system (MPS). The particles were coated with a single lipid bilayer (SLB) 
containing 1:1:0.5 (by mol) DOPC/cholesterol/DSPE-PEG2K (DOPC= 1,2-dioleoyl-sn-
glycero-3-phosphocholine, DSPE-PEG2K= 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]). The lipid solution (in THF) 
was combined with a THF solution of nanoparticles, followed by removal of THF and 
dispersion in 30% ethanol in water. The presence of the lipid coating was confirmed by 
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TEM, DLS, TGA, and cisplatin release data. The TEM images of both Ca-PtBP@Lipid and 
Mn-PtBP@Lipid show monodisperse particles (Figure 4.3). Additionally, DLS 
measurements of the lipid-coated particles confirm an increase in size and a decrease in PDI 
due to the presence of the SLB (Table 4.2). For instance, after lipid coating nanoparticle Ca-
PtBP, the PDI decreased from 0.281 to 0.155 indicating a more monodisperse sample. The 
lipid coating helped to reduce the amount of nanoparticle aggregation observed in solution. 
Scheme 4.5. Lipid coating of PtBP nanoparticles with 1:1:0.5 (by mol) 
DOPC/cholesterol/DSPE-PEG2K. 
 
Cl
Pt
NH3
NH3Cl
Cl
Pt
NH3
NH3Cl
Lipid
HO
H
H
H
=
Cholesterol
=
=
O
O H
OO
O
DSPE-PEG2K
P O
O- O
DOPC O
O H
OO
O
P
O
O O N
H
N (OCH2CH2)45OCH3
O
86 
 
Figure 4.3. TEM images of (a) Ca-PtBP@Lipid and (b) Mn-PtBP@Lipid. 
Table 4.2. DLS measurements for Ca-PtBP@Lipid and Mn-PtBP@Lipid obtained in 5 mM 
PBS. 
Nanoparticle Z Average (nm) PDI 
Number 
Average (nm) 
Ca-PtBP@Lipid 130.8 0.155 81.44 
Mn-PtBP@Lipid 141.6 0.087 103.7 
Ca-control@Lipid 170.1 0.325 50.22 
Mn-control@Lipid 156.5 0.411 46.43 
 
4.3.4 BSA Stability Assay of Ca-PtBP@Lipid and Mn-PtBP@Lipid 
Proteins found in the body tend to adsorb onto the surface of nanoparticles via non-
specific adsorption limiting their use in vivo.79 The mononuclear phagocyte system (MPS) 
recognizes the protein-covered nanoparticle as a foreign body and immediately clears it from 
the body. In drug delivery, the nanoparticle needs to circulate the body until it reaches the 
desired target  (i.e. the tumor region). PEG has been shown to reduce protein adsorption and 
thus inhibit macrophage uptake. The incorporation of PEG into the liposomal formulation 
should increase the stability of Ca-PtBP@Lipid and Mn-PtBP@Lipid in the presence of 
proteins. To confirm this, the particles were combined with bovine serum albumin (BSA), 
and DLS measurements were obtained over time. Albumin is the most abundant blood 
                                                
79 Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Adv. 
Drug Delivery Rev. 2009, 61, 428-437. 
a) b) 
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plasma protein, so it was selected as a model to study protein interaction with the synthesized 
nanoparticles. If BSA adsorbed onto the surface of the nanoparticles, an increase in particle 
size would be observed. To conduct this study, the nanoparticles were combined with BSA, 
and DLS measurements were recorded every 10 minutes for 12 hours. The BSA stability 
results for Mn-PtBP@Lipid are shown in Figure 4.4. The particle size remained relatively 
constant indicating the PEG-containing SLB prevented non-specific protein adsorption. 
 
Figure 4.4. Z Average (nm) of Mn-PtBP@Lipid as a function of BSA exposure time. 
 
4.3.5 Cisplatin Release from Ca-PtBP and Mn-PtBP 
Drug delivery nanoparticles must be stable enough to circulate the body, yet still 
release the active agent after reaching the tumor site. Incubating a known amount of particle 
in PBS allowed the in vitro particle degradation to be monitored. Nanoparticle samples were 
enclosed in dialysis bags (MW cut-off 10,000) and dialyzed in PBS at 37 °C. At 
predetermined time points, 500 µL of sample was removed from the incubation medium. To 
determine the amount of cisplatin released from the particles into the medium, the sample 
88 
was digested in 2% nitric acid and ICP-MS data was obtained. As shown in Figure 4.5 and 
Figure 4.6, the as-synthesized particles demonstrated fast drug release. However, after lipid 
coating, the particles were stabilized and cisplatin release occurred at a much slower rate. 
 
Figure 4.5. Platinum release from Ca-PtBP and Ca-PtBP@Lipid. 
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Figure 4.6. Platinum release from Mn-PtBP and Mn-PtBP@Lipid. 
 
4.3.6 Anisamide Targeting of PtBP Nanoparticles 
A wide range of cancers, including non-small cell lung, breast, and prostate, 
overexpress sigma receptors on the cancer cell surface.80,81,82 The small molecule anisamide 
(AA) has been used as a ligand to target drugs to sigma receptors on cancer cells in vitro.80 
The targeting ligand AA was attached to the end of DSPE-PEG (MW= 2000) to form DSPE-
PEG-AA. This tumor-targeting lipid was incorporated into the liposomal formulation used 
when coating the nanoparticles with SLBs. In the lipid coating procedure described 
previously, DSPE-PEG2K was substituted with DSPE-PEG2K and DSPE-PEG2K-AA in a 9:1 
molar ratio forming particles Ca-PtBP@LipidAA and Mn-PtBP@LipidAA. As 
                                                
80 Aydar, E.; Palmer, C. P.; Djamgoz, M. B. A. Cancer Res. 2004, 64, 5029-5035. 
 
81 Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Int. J. Cancer 2004, 112, 693-700. 
 
82 John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Cancer Res. 1999, 59, 
4578-4583. 
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demonstrated by TEM and DLS (Figure 4.7 and Table 4.3), both AA-targeted systems 
display similar sizes and morphologies to their non-targeted lipid coated analogs.  
 
Figure 4.7. TEM images of (a) Ca-PtBP@LipidAA and (b) Mn-PtBP@LipidAA. 
 
Table 4.3. DLS measurements for Ca-PtBP@Lipid and Mn-PtBP@Lipid obtained in 5 mM 
PBS. 
Nanoparticle Z Average (nm) PDI Number Average (nm) 
Ca-PtBP@LipidAA 121.5 0.166 72.58 
Mn-PtBP@LipidAA 169.6 0.188 119.5 
 
4.3.7 In Vitro Cytotoxicity Assays 
The cytotoxicity of the synthesized control and PtBP nanoparticles was tested against 
human lung cancer cell lines. The lipid-coated PtBP systems were tested against both A549 
(Figure 4.8) and H460 (Figure 4.9) non-small cell lung cancer cells. In both of these assays, 
the lipid-coated particles demonstrated decreased efficacy when compared to the small 
molecule counterparts, cisplatin and PtBP. As demonstrated by the drug release profile, the 
lipid-coated particles are expected to stable for a long period of time, which most likely leads 
to an increase in IC50 values when compared to the small molecules. In the nanoparticle 
form, a sustained drug release is observed. Figure 4.10 shows the results of an assay against 
H460 cells using AA-targeted MnPtBP nanoparticles. In this assay, small molecule cisplatin 
and the monomer PtBP displayed similar efficacy, while MnPt@Lipid and 
MnPtBP@LipidAA were less effective (see Table 2.4 for IC50 values).  No enhanced 
a) b) 
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cytotoxicity was observed for the AA-targeted particles, indicating that targeting is not 
necessary when moving the particles into an in vivo model. 
 
Figure 4.8. Cell viability assays of cisplatin (black), PtBP (red), MnPtBP@Lipid (green), 
and CaPtBP@Lipid (blue) evaluated against A549 human non-small cell lung cancer line. 
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Figure 4.9. Cell viability assays of cisplatin (black), PtBP (red), MnPtBP@Lipid (green), 
and CaPtBP@Lipid (blue) evaluated against H460 human non-small cell lung cancer line. 
 
 
Figure 4.10. Cell viability assays of cisplatin (blue), PtBP (red), MnPtBP@Lipid (green), 
MnControl@Lipid (light blue), and MnPtBP@LipidAA (purple) evaluated against H460 
human non-small cell lung cancer. 
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4.4 Conclusions 
In conclusion, two PtBP nanoparticle systems were developed with high loadings of 
cisplatin-based chemotherapeutics (~20-25%). After lipid coating, these particles 
demonstrate slow drug release with t1/2> 70 h for MnPtBP@Lipid and CaPtBP@Lipid. The 
slow drug release is ideal when translating the nanoparticles into in vivo applications because 
it demonstrates the potential to circulate the blood stream much longer than the small 
molecule agent. The Pt(IV) prodrug incorporated into the nanoparticle would be released 
once the nanoparticle reaches the reducing environment present in the tumor region. By 
incorporating PEG into the liposomal formulation, the blood circulation time would also 
increase due to shielding from the MPS. The presence of the AA-targeting ligand on the 
nanoparticle surface did not enhance the cytotoxic effects of the nanoparticle, indicating that 
targeting is not necessary for these systems. 
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